

HEALTH ANNUAL STATEMENT

FOR THE YEAR ENDED DECEMBER 31, 2024 OF THE CONDITION AND AFFAIRS OF THE

AMH Health Plans of Maine, Inc.

NAIC Group	O Code 0671 067 (Current) (Pric		de <u>16774</u> Employer's ID	Number <u>84-41816</u>	95
Organized under the Laws of	Maine		State of Domicile or Port of Enti	ry	ME
Country of Domicile		United States	of America		
Licensed as business type:		Oth	er		
Is HMO Federally Qualified? Yes [] No []				
Incorporated/Organized	01/02/2020		Commenced Business	04/2	2/2020
Statutory Home Office	2 Gannett Drive	<u> </u>	So	outh Portland, ME, US 041	106
	(Street and Numb			Town, State, Country and 2	
Main Administrative Office		2 Gannet			
South	Portland, ME, US 04106	(Street and	Number)	866-583-6182	
(City or Town	, State, Country and Zip Cod	e)	(Are	ea Code) (Telephone Num	ber)
Mail Address	2 Gannett Drive	,		outh Portland, ME, US 041	
	(Street and Number or P.O.	Box)	(City or 1	Γown, State, Country and Σ	Zip Code)
Primary Location of Books and Reco	ords	220 Virgini (Street and			
	napolis, IN, US 46204			317-488-6000	
(City or Town	ı, State, Country and Zip Cod	e)	(Are	ea Code) (Telephone Num	ber)
Internet Website Address		www.elevance	ehealth.com		
Statutory Statement Contact	Leigh	Barrett me)	,	317-432-6988 (Area Code) (Telephone	
leigh.ba	rrett@elevancehealth.com	,		317-488-6200	number)
	(E-mail Address)			(FAX Number)	
D	Destro Medic O	OFFIC		\(\tau_{	1 1 0 - 1
President and Chairperson Secretary			I reasurer Assistant Treasurer	Vincent Ed	Kenneth Noble
, <u></u>		ОТН			
		DIRECTORS O	R TRUSTEES		
James Robert Ke		Francis Georgian Franci			R Bayman # pert Chamberlin #
Denise Marie Sr					
State of County of	Indiana Marion	– ss			
-		_			
The officers of this reporting entity be all of the herein described assets we statement, together with related exhocondition and affairs of the said repin accordance with the NAIC Annual rules or regulations require difference respectively. Furthermore, the scopexact copy (except for formatting difference in the said copy (except for formatting difference).	vere the absolute property of ibits, schedules and explanat orting entity as of the reportin al Statement Instructions and ences in reporting not relate be of this attestation by the d	the said reporting entity, ions therein contained, ar g period stated above, and Accounting Practices and d to accounting practice escribed officers also incl	free and clear from any liens of the second or referred to, is a full and of its income and deductions to Procedures manual except to a and procedures, according ludes the related corresponding	or claims thereon, except during statement of all the herefrom for the period en the extent that: (1) state I to the best of their informelectronic filing with the N	as herein stated, and that assets and liabilities and of ded, and have been comple aw may differ; or, (2) that s mation, knowledge and be VAIC, when required, that is
to the enclosed st Signed by:	. /	Signed	by:		—DocuSigned by:
Venise Si	mith	kathi	, kiefer		Vincent E. Scher
Denise Marie Smith President and Chairper		D85175 Kaulieeli Su Secre		Vince	— A85A33722D4143E nt Edward Scher Treasurer
Subscribed and sworn to before me 10th day of Feb Louanna Stiner Executive Admin Assistant 06/29/31			a. Is this an original filing? b. If no, 1. State the amendme 2. Date filed	nt number	Yes[X]No[]

ASSETS

			Current Year		Prior Year
		1 Assets	2 Nonadmitted Assets	3 Net Admitted Assets (Cols. 1 - 2)	4 Net Admitted Assets
1.	Bonds (Schedule D)				118,552
2.	Stocks (Schedule D):				
	2.1 Preferred stocks			0	0
	2.2 Common stocks			0	0
3.	Mortgage loans on real estate (Schedule B):				
	3.1 First liens			0	0
	3.2 Other than first liens			0	0
4.	Real estate (Schedule A):				
	4.1 Properties occupied by the company (less \$				
	encumbrances)			0	0
	4.2 Properties held for the production of income (less				
	\$ encumbrances)			0	0
	4.3 Properties held for sale (less \$				
	encumbrances)			0	0
5.	Cash (\$6, 183, 987 , Schedule E - Part 1), cash equivalents				
	(\$, Schedule E - Part 2) and short-term				
	investments (\$, Schedule DA)	6, 183, 987		6, 183, 987	5,398,036
6.	Contract loans, (including \$ premium notes)			0	0
7.	Derivatives (Schedule DB)				
8.	Other invested assets (Schedule BA)				
9.	Receivables for securities				
10.	Securities lending reinvested collateral assets (Schedule DL)			0	0
11.	Aggregate write-ins for invested assets	0	0	0	0
12.	Subtotals, cash and invested assets (Lines 1 to 11)	6,300,568	0	6,300,568	5,516,588
13.	Title plants less \$ charged off (for Title insurers				
	only)			0	0
14.	Investment income due and accrued	2,375	1,500	875	875
15.	Premiums and considerations:				
	15.1 Uncollected premiums and agents' balances in the course of collection	27 , 136	15,431	11,705	3,850
	15.2 Deferred premiums, agents' balances and installments booked but				
	deferred and not yet due (including \$				
	earned but unbilled premiums)			0	0
	15.3 Accrued retrospective premiums (\$45,849) and				
	contracts subject to redetermination (\$278,297)	324 , 146		324 , 146	250,625
16.	Reinsurance:				
	16.1 Amounts recoverable from reinsurers			0	0
	16.2 Funds held by or deposited with reinsured companies			0	0
	16.3 Other amounts receivable under reinsurance contracts				
17.	Amounts receivable relating to uninsured plans	535,272		535,272	33,606
18.1	Current federal and foreign income tax recoverable and interest thereon \ldots			0	0
18.2	Net deferred tax asset			0	0
19.	Guaranty funds receivable or on deposit			0	0
20.	Electronic data processing equipment and software			0	0
21.	Furniture and equipment, including health care delivery assets				
	(\$)				
22.	Net adjustment in assets and liabilities due to foreign exchange rates				
23.	Receivables from parent, subsidiaries and affiliates				
24.	Health care (\$85,220) and other amounts receivable				
25.	Aggregate write-ins for other-than-invested assets	210	210	0	0
26.	Total assets excluding Separate Accounts, Segregated Accounts and Protected Cell Accounts (Lines 12 to 25)	7 222 001	76 115	7 257 706	6 475 000
27.	From Separate Accounts, Segregated Accounts and Protected Cell				
28.	Accounts	7,333,901	76.115	7,257,786	
20.	DETAILS OF WRITE-INS	7,000,001	70,110	7,207,700	0,470,000
1101					
1101.					
1102.					
1103.	Summary of remaining write ine for Line 11 from everflow page				
1198.	Summary of remaining write-ins for Line 11 from overflow page	0		0	
1199.	Totals (Lines 1101 through 1103 plus 1198)(Line 11 above)	-		0	0
2501.	Prepaid expenses			0	
2502.					
2503.					
2598.	Summary of remaining write-ins for Line 25 from overflow page				
2599.	Totals (Lines 2501 through 2503 plus 2598)(Line 25 above)	210	210	0	0

LIABILITIES, CAPITAL AND SURPLUS

	LIADILITILO, CAF			-	Dries Vees
	-	1	Current Year 2	3	Prior Year
		'	2	3	4
		Covered	Uncovered	Total	Total
1.	Claims unpaid (less \$0 reinsurance ceded)	1,114,736		1,114,736	1,358,310
2.	Accrued medical incentive pool and bonus amounts	103.611		103,611	53.270
3.	Unpaid claims adjustment expenses			22,978	
		22,370		22,370	
4.	Aggregate health policy reserves, including the liability of				
	\$0 for medical loss ratio rebate per the Public				
	Health Service Act	4,045		4,045	1,030,010
5.	Aggregate life policy reserves			0	0
6.	Property/casualty unearned premium reserves			0	0
7.	Aggregate health claim reserves				
	Premiums received in advance				
8.					
9.	General expenses due or accrued	2,197		2,197	
10.1	Current federal and foreign income tax payable and interest thereon				
	(including \$ on realized capital gains (losses))			0	0
10.2	Net deferred tax liability			0	0
11.	Ceded reinsurance premiums payable			0	0
12.	Amounts withheld or retained for the account of others				
	Remittances and items not allocated	•		*	·
13.		23, 103		23, 103	0,201
14.	Borrowed money (including \$ current) and				
	interest thereon \$ (including				
	\$ current)			0	0
15.	Amounts due to parent, subsidiaries and affiliates	575,985		575,985	0
16.	Derivatives				
	Payable for securities.				
17.	· ·				
18.	Payable for securities lending			0	0
19.	Funds held under reinsurance treaties (with \$				
	authorized reinsurers, \$0 unauthorized				
	reinsurers and \$0 certified reinsurers)			0	0
20.	Reinsurance in unauthorized and certified (\$				
_0.	companies			0	0
0.4	·				
21.	Net adjustments in assets and liabilities due to foreign exchange rates				0
22.	Liability for amounts held under uninsured plans			0	87,039
23.	Aggregate write-ins for other liabilities (including \$				
	current)	15,221	0	15,221	7,299
24.	Total liabilities (Lines 1 to 23)	1,865,388	0	1,865,388	2,585,421
25.	Aggregate write-ins for special surplus funds				
26.	Common capital stock				
27.	Preferred capital stock				
28.	Gross paid in and contributed surplus				
29.	Surplus notes	XXX	XXX		
30.	Aggregate write-ins for other-than-special surplus funds	XXX	XXX	0	0
31.	Unassigned funds (surplus)				
	Less treasury stock, at cost:			, , , ,	, , , ,
02.	•				
	32.1 shares common (value included in Line 26				
	\$	XXX	XXX		0
	32.2 shares preferred (value included in Line 27				
	\$	XXX	XXX		
33.	Total capital and surplus (Lines 25 to 31 minus Line 32)	XXX	XXX	5,392,398	3,890,575
34.	Total liabilities, capital and surplus (Lines 24 and 33)	XXX	XXX	7,257,786	6,475,996
01.		7001	7001	7,207,700	0,110,000
	DETAILS OF WRITE-INS	45.004			
2301.	Medicare Part D overpayment	15,221	0	15,221	
2302.					
2303.					
2398.	Summary of remaining write-ins for Line 23 from overflow page	0	0	0	0
	Totals (Lines 2301 through 2303 plus 2398)(Line 23 above)	15,221	0	15,221	7,299
	· · · · · · · · · · · · · · · · · · ·	,		,	
2598.	Summary of remaining write-ins for Line 25 from overflow page	XXX	XXX	0	0
	Totals (Lines 2501 through 2503 plus 2598)(Line 25 above)	xxx	xxx	0	0
	Totals (Ellies 2001 tillodgii 2000 pids 2000)(Ellie 20 dbove)				
3098.	Summary of remaining write-ins for Line 30 from overflow page	XXX	XXX	0	0
	Totals (Lines 3001 through 3003 plus 3098)(Line 30 above)	XXX	XXX	0	0
	,		L		

STATEMENT OF REVENUE AND EXPENSES

	Curren	t Year	Prior Year
	1 Uncovered	2 Total	3 Total
1. Member Months			
1. World World S.			
Net premium income (including \$ non-health premium income)	xxx	8,170,377	8,334,167
Change in unearned premium reserves and reserve for rate credits	xxx	94,831	(14,010)
4. Fee-for-service (net of \$ medical expenses)	xxx	0	0
5. Risk revenue			0
Aggregate write-ins for other health care related revenues			0
Aggregate write-ins for other non-health revenues			
8. Total revenues (Lines 2 to 7)			
Hospital and Medical:			
9. Hospital/medical benefits		4,833,963	5,519,485
10. Other professional services		594,566	643,848
11. Outside referrals		0	0
12. Emergency room and out-of-area		485,418	1, 120, 190
13. Prescription drugs		707,617	378,599
14. Aggregate write-ins for other hospital and medical	0	0	0
15. Incentive pool, withhold adjustments and bonus amounts			98,745
16. Subtotal (Lines 9 to 15)			7,760,867
Less;		, ,	, ,
17. Net reinsurance recoveries		0	0
18. Total hospital and medical (Lines 16 minus 17)	0	6,862,880	7,760,867
19. Non-health claims (net)			
20. Claims adjustment expenses, including \$		257,746	421,259
21. General administrative expenses		706,133	1, 136, 049
22. Increase in reserves for life and accident and health contracts (including \$		·	
increase in reserves for life only)		(953.194)	(1.081.050)
23. Total underwriting deductions (Lines 18 through 22)			
24. Net underwriting gain or (loss) (Lines 8 minus 23)			
25. Net investment income earned (Exhibit of Net Investment Income, Line 17)			
26. Net realized capital gains (losses) less capital gains tax of \$			
27. Net investment gains (losses) (Lines 25 plus 26)			
Net gain or (loss) from agents' or premium balances charged off [(amount recovered)]		109,302	100,507
		(2.272)	(1.061)
-			
		003 .	(854)
30. Net income or (loss) after capital gains tax and before all other federal income taxes (Lines 24 plus 27 plus 28 plus 29)	xxx	1,499,395	181,704
31. Federal and foreign income taxes incurred	xxx		
32. Net income (loss) (Lines 30 minus 31)	XXX	1,499,395	181,704
DETAILS OF WRITE-INS			
0601.	xxx		
0602.	xxx		
0603	xxx		
0698. Summary of remaining write-ins for Line 6 from overflow page	xxx	0	0
0699. Totals (Lines 0601 through 0603 plus 0698)(Line 6 above)	XXX	0	0
0701.	XXX		
0702.	XXX		
0703	XXX		
0798. Summary of remaining write-ins for Line 7 from overflow page	XXX	0	0
0799. Totals (Lines 0701 through 0703 plus 0798)(Line 7 above)	XXX	0	0
1401.			
1402.			
1403.			
1498. Summary of remaining write-ins for Line 14 from overflow page			0
1499. Totals (Lines 1401 through 1403 plus 1498)(Line 14 above)	0	0	<u> </u>
2901. Other Income (expense)			(854)
2902.			
2903			
2998. Summary of remaining write-ins for Line 29 from overflow page			0
2999. Totals (Lines 2901 through 2903 plus 2998)(Line 29 above)	0	663	(854)

STATEMENT OF REVENUE AND EXPENSES (Continued)

	STATEMENT OF REVENUE AND EXPENSES	Oontinaec	
		Current Year	2 Prior Year
	CAPITAL AND SURPLUS ACCOUNT		
33.	Capital and surplus prior reporting year	3.890.575	3.749.378
34.	Net income or (loss) from Line 32		
35.	Change in valuation basis of aggregate policy and claim reserves		
36.	Change in net unrealized capital gains (losses) less capital gains tax of \$		
37.	Change in net unrealized foreign exchange capital gain or (loss)		
38.	Change in net deferred income tax		
39.	Change in nonadmitted assets		(40,507
40	Change in unauthorized and certified reinsurance	0	0
41.	Change in treasury stock	0	0
42.	Change in surplus notes	0	0
43.	Cumulative effect of changes in accounting principles		
44.	Capital Changes:		
	44.1 Paid in	0	0
	44.2 Transferred from surplus (Stock Dividend)	0	0
	44.3 Transferred to surplus		
45.	Surplus adjustments:		
	45.1 Paid in	0	0
	45.2 Transferred to capital (Stock Dividend)		
	45.3 Transferred from capital		
46.	Dividends to stockholders		
47.	Aggregate write-ins for gains or (losses) in surplus	0	0
48.	Net change in capital and surplus (Lines 34 to 47)		141, 196
49.	Capital and surplus end of reporting period (Line 33 plus 48)	5,392,398	3,890,575
	DETAILS OF WRITE-INS	.,,	-, -, -
4701.	DETAILS OF WATE-ING		
4701.			
4703.			
4798.	Summary of remaining write-ins for Line 47 from overflow page		0
4799.	Totals (Lines 4701 through 4703 plus 4798)(Line 47 above)	0	

CASH FLOW

		1	2
			Prior Year
	Cook from Operations	Current Year	Phor fear
1.	Cash from Operations Premiums collected net of reinsurance	8 004 403	0 244 260
2.	Net investment income		
3.	Miscellaneous income	· _	02,990
	Total (Lines 1 through 3)		8,447,364
4.	,		· · · · ·
5.	Benefit and loss related payments		7,302,620
6.	Net transfers to Separate Accounts, Segregated Accounts and Protected Cell Accounts		
7.	Commissions, expenses paid and aggregate write-ins for deductions		
8.	Dividends paid to policyholders		
9.	Federal and foreign income taxes paid (recovered) net of \$ tax on capital gains (losses)		0 000 547
	Total (Lines 5 through 9)		9,088,547
11.	Net cash from operations (Line 4 minus Line 10)	(426,678)	(641, 183)
	Cash from Investments		
12.	Proceeds from investments sold, matured or repaid:		
	12.1 Bonds		0
	12.2 Stocks		0
	12.3 Mortgage loans		
	12.4 Real estate		
	12.5 Other invested assets		0
	12.6 Net gains or (losses) on cash, cash equivalents and short-term investments		0
	12.7 Miscellaneous proceeds		0
	12.8 Total investment proceeds (Lines 12.1 to 12.7)	0	0
13.	Cost of investments acquired (long-term only):		
	13.1 Bonds		10,702
	13.2 Stocks		0
	13.3 Mortgage loans		0
	13.4 Real estate	0	0
	13.5 Other invested assets	0	0
	13.6 Miscellaneous applications	0	0
	13.7 Total investments acquired (Lines 13.1 to 13.6)	0	10,702
14.	Net increase/(decrease) in contract loans and premium notes	0	0
15.	Net cash from investments (Line 12.8 minus Line 13.7 minus Line 14)	0	(10,702)
	Cash from Financing and Miscellaneous Sources		
16.	Cash provided (applied):		
	16.1 Surplus notes, capital notes		0
	16.2 Capital and paid in surplus, less treasury stock	0	0
	16.3 Borrowed funds	0	0
	16.4 Net deposits on deposit-type contracts and other insurance liabilities	0	0
	16.5 Dividends to stockholders	0	0
	16.6 Other cash provided (applied)	1,212,629	(696, 105)
17.	Net cash from financing and miscellaneous sources (Lines 16.1 to 16.4 minus Line 16.5 plus Line 16.6)	1,212,629	(696, 105)
	RECONCILIATION OF CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS		
18.	Net change in cash, cash equivalents and short-term investments (Line 11, plus Lines 15 and 17)	785,951	(1,347,990)
19.	Cash, cash equivalents and short-term investments:	,	, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
	19.1 Beginning of year	5,398,036	6,746,026

Note: Supplemental disclosures of cash flow information for non-cash transactions:		

ANALYSIS OF OPERATIONS BY LINES OF BUSINESS

Processing						<u> </u>				<u> </u>	0					
Not premise informs			1	Compre	hensive	4	5	6	7	8	9	10	11	12	13	14
Note statement receives																
Val prosum recents Val prosum recent recent recent Val prosum recent rece				2	3											
1. Not permission improves a common sequences and minimore 1. No. 200 1. No.					_											
2. Charge in susmand premise in reserves and seaver for feature for the premise of the premise o					Group	Supplement	Vision Only	Dental Only	Benefits Plan		Medicaid	Credit A&H	Income	Care	Other Health	Non-Health
Fair increeds	1.	Net premium income	8 , 170 , 377													
Fair increeds	2.	Change in unearned premium reserves and reserve														
Management Man			94,831							94,831						
Management Man	3		. , .							. , .						
4. Risk service	0.		0													VVV
S. Aggregate with the following the feel for the feel four evaluated previous and the following the feel feel feel feel feel feel feel fe		. ,														
Feministrate			0													XXX
Principles	5.		0	0	0	0	0	0	0	0	0	0	0	0	0	XXX
Principles Color	6	Aggregate write-ins for other non-health care related														
7. Total recentures (Lines 10 to)	٥.		0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	0
8 Hoopselmedical benefits	7			0	Λ	n	n	n	0		0	Λ	0	n	Λ	0
S Other professional services 94,66																
10 Dubles referrals	_															
11 Emergency room and out-of-area	٥.		, .							594,566						
12 Pescription drugs																
12 Prescription drugs	11.	Emergency room and out-of-area								485,418						XXX
13 Aggregate with-risk of other hospital and medical 0 0 0 0 0 0 0 0 0		0 ,	707.617							707.617						
14 Incentive pool, withhold adjustments and bonus analysis and provided adjustments and bonus analysis and provided adjustment and bonus analysis and provided adjustment and provided adjustment and provided adjustment adjustment and provided adjustment adjustm			,	0	0	0	0	0	0	,	0	Λ	0	0	Λ	
arrounts			0							l						
15 Substat (Lines 10 14)	14.		044 040							044 040						V0/0/
15 Not reinsurance recoveries 0 0 0 0 0 0 0 0 0	1															
17 Total medical and hospital (Lines 15 minus 16)			, ,	0	0	0	0	0	0	6,862,880	0	0	0	0	0	
18 Non-health claims (net)			•••••••••													
18 Non-health claims (ref)	17.	Total medical and hospital (Lines 15 minus 16)	6,862,880	0	0	0	0	0	0	6,862,880	0	0	0	0	0	XXX
19, Claims adjustment expenses including S			0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
S . 145,582 cost containment expenses				700							,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,					
20 General administrative expenses 76, 133	19.		057 746							057 746						
21 Increase in reserves for accident and health contracts			. ,													
Contracts		•	706, 133							706, 133						
22 Increase in reserves for life contracts 0 XXX X	21.	Increase in reserves for accident and health														
23. Total underwriting deductions (Lines 17 to 22)			(953 , 194)							(953, 194)						XXX
24. Net underwriting gain or (loss) (Line 7 minus Line 23)	22.	Increase in reserves for life contracts	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
24. Net underwriting gain or (loss) (Line 7 minus Line 23)	23	Total underwriting deductions (Lines 17 to 22)	6 873 565	0	0	0	0	0	0	6 873 565	0	0	0	0	0	0
23												•				
DETAILS OF WRITE-INS	24.	net underwriting gain of (loss) (Line / minus Line	1 201 6/2	0	0	٥	0	0	0	1 201 6/2	0	0	0	0	0	٥
5501	-		1,051,040	U	U	U	U	U	U	1,001,040	U	U	U	U	U	U
SSUM Summary of remaining write-ins for Line 5 from overflow page		DETAILS OF WRITE-INS														
0503 0508 Summary of remaining write-ins for Line 5 from overflow page 0 0 0 0 0 0 0 0 0	0501.															XXX
0503 0508 Summary of remaining write-ins for Line 5 from overflow page 0 0 0 0 0 0 0 0 0	0502.						.									XXX
0598 Summary of remaining write-ins for Line 5 from overflow page					L	L	1			L				L	L	
Overflow page		Summary of remaining write-ine for Line F from			[[
0599 Totals (Lines 0501 through 0503 plus 0598) (Line 5 0 0 0 0 0 0 0 0 0	0090.		n	n	n	n	n	n	0	n	n	٨	n	n	n	XXX
above	0500		0				l			J		0				
0601	0599.		•	_	_	_	1 _	_	_	1		^	_	_	_	V0.07
0602	-	, , , , , , , , , , , , , , , , , , ,	0	•	0	Ū	Ū	0	0	U	0		0	0	0	XXX
0603																
0698. Summary of remaining write-ins for Line 6 from overflow page	0602.			XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
0698. Summary of remaining write-ins for Line 6 from overflow page	0603.			XXX	XXX	XXX	XXX	XXX	XXX	xxx	XXX	XXX	XXX	xxx	XXX	
overflow page		Summary of remaining write-ins for Line 6 from														
Totals (Lines 0601 through 0603 plus 0698) (Line 6	0000.		n	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	n
above 0 XXX	0600															
1301	0099.		^	VVV	VVV	VVV	VVV	VVV	VVV	VVV	VVV	VVV	VVV	VVV	VVV	^
1302		above)	U	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	J. 0
1303.										ļ						
1398. Summary of remaining write-ins for Line 13 from overflow page	1302.						.									
1398. Summary of remaining write-ins for Line 13 from overflow page	1303.						.									XXX
overflow page 0 <		Summary of remaining write-ins for Line 13 from								İ						
1399. Totals (Lines 1301 through 1303 plus 1398) (Line 13			n	n	n	n	n	n	n	l	n	n	n	n	n	XXX
	1200	1 0								I		0				
1 above) 1 0 0 0 0 0 0 0 0 0 0 0 0 XXX	1399.		0	^	0	^	_	0	0	_	۸	۸	^	0	۸	VVV
		above)	U	U	ı U	ı v	1 0	U	U	1 0	U	U	U		U	۸۸۸

_

m

ANNUAL STATEMENT FOR THE YEAR 2024 OF THE AMH Health Plans of Maine, Inc.

UNDERWRITING AND INVESTMENT EXHIBIT

PART 1 - PREMILIMS

PART 1 - PREMIUMS	1	2	3	4
Line of Business	Direct Business	Reinsurance Assumed	Reinsurance Ceded	Net Premium Income (Cols. 1 + 2 - 3)
1. Comprehensive (hospital and medical) individual				0
Comprehensive (hospital and medical) group				0
3. Medicare Supplement				0
4. Vision only				0
5. Dental only				0
6. Federal Employees Health Benefits Plan	0			0
7. Title XVIII - Medicare	8,170,377			8,170,377
8. Title XIX - Medicaid	0			0
9. Credit A&H				0
10. Disability Income				0
11. Long-Term Care				0
12. Other health				0
13. Health subtotal (Lines 1 through 12)	8,170,377	0	0	8,170,377
14. Life	0			0
15. Property/casualty	0			0
16. Totals (Lines 13 to 15)	8,170,377	0	0	8,170,377

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2 - CLAIMS INCURRED DURING THE YEAR

		1	Compreh (Hospital &		4	5	6	7	8	9	10	11	12	13	14
		Total	2 Individual	3 Group	Medicare Supplement	Vision Only	Dental Only	Federal Employees Health Benefits Plan	Title XVIII Medicare	Title XIX Medicaid	Credit A&H	Disability Income	Long-Term Care	Other Health	Other Non-Health
1.	Payments during the year:														
	1.1 Direct	6,880,232							6,880,232						
	1.2 Reinsurance assumed	0													
	1.3 Reinsurance ceded	0													
	1.4 Net	6,880,232	0	0	0	0	0	0	6,880,232	0	0	0	0	0	C
2.	Paid medical incentive pools and bonuses	190,975							190,975						
3.	Claim liability December 31, current year from Part 2A:														
	3.1 Direct	1, 114,736	0	0	0	0	0	0	1,114,736	0	0	0	0	0	(
	3.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0	0	0	0	(
	3.3 Reinsurance ceded	0	0 .	0	0	0	0	0	0	0	0	0	0	0	
	3.4 Net	1, 114,736	0	0	0	0	0	0	1,114,736	0	0	0	0	0	
4.	Claim reserve December 31, current year from Part 2D:	0													
	4.1 Direct	0 0													
	4.2 Reinsurance assumed														
	4.3 Reinsurance ceded	0													
	4.4 Net	0	0	0	0	0	0	0	0	0	0	0	0	0	(
	Accrued medical incentive pools and bonuses, current year	103,611							103,611						
	Net health care receivables (a)	15,094							15,094						
7.	Amounts recoverable from reinsurers December 31, current year	0													
8.	Claim liability December 31, prior year from Part 2A:		_	_	_		_			_	_		_	_	
	8.1 Direct	1,358,310	0	0	0	0	0	0	1,358,310	0	0	0	0	0	(
	8.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0	0	0	0	(
	8.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	0	0	0	0	
	8.4 Net	1,358,310	0	0	0	0	0	0	1,358,310	0	0	0	0	0	
9.	Claim reserve December 31, prior year from Part 2D:	•													
	9.1 Direct	0 0													
	9.2 Reinsurance assumed	0													
	9.3 Reinsurance ceded														
	9.4 Net	0	0	0	0	J0	0	0	0	J0	0	0	0	0	ļ
	Accrued medical incentive pools and bonuses, prior year	53,270							53,270						
11.	Amounts recoverable from reinsurers December 31, prior year	0													
12.	Incurred Benefits:	6,621,564	0	0	0	0	0	0	6,621,564	0	0	0	0	0	
	12.2 Reinsurance assumed	0,021,004	0	0	0	0	0	0	0,021,004	0	0	0	0	0	(
	12.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	0	0	0	0	r
	12.4 Net	6.621.564	0	0	0		_	0	6,621,564	0	0	0	, ,		,
13	Incurred medical incentive pools and	0,021,004	"	0	0	0	0	0	0,021,004	0	0	0	1	0	
13.	bonuses	241,316	0	0	0	0	0	0	241,316	0	0	0	0	0	0

⁽a) Excludes \$ loans or advances to providers not yet expensed.

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2A - CLAIMS LIABILITY END OF CURRENT YEAR

					T 2A - CLAIMS		D OF CURKEN				1		1	,
	1		hensive	4	5	6	7	8	9	10	11	12	13	14
		(Hospital	& Medical)	_			Federal							
		2	3				Employees							
				Medicare			Health	Title XVIII	Title XIX		Disability	Long-Term		Other
	Total	Individual	Group	Supplement	Vision Only	Dental Only	Benefits Plan	Medicare	Medicaid	Credit A&H	Income	Care	Other Health	Non-Health
Reported in Process of Adjustment:														
1.1 Direct	524.813							524,813						
1.2 Reinsurance assumed	1 , 1													
1.3 Reinsurance ceded														
1.4 Net	524,813	0	0	0	0	0	0	524,813	0	0	0	0	0	0
Incurred but Unreported:														
2.1 Direct	589.923							589.923						
	,							,						
2.2 Reinsurance assumed														
2.3 Reinsurance ceded	0 .													
2.4 Net	589,923	0	0	0	0	0	0	589,923	0	0	0	0	0	0
Amounts Withheld from Paid Claims and Capitations:														
·														
3.1 Direct														
3.2 Reinsurance assumed	0													
3.3 Reinsurance ceded	0 .													
3.4 Net	0	0	0	0	0	0	0	0	0	0	0	0	0	0
			-											
4. TOTALS:														
4.1 Direct			0	0	0	0	0	1, 114,736	0	0	0	0	0	0
4.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0	0	0	0	0
4.3 Reinsurance ceded	0	0		0	0		0	0	0	0	0	0	0	0
4.4 Net	1,114,736	0	0		0		0	1,114,736	0	0	0	0	0	0
4.4 INEL	1, 114,730	U	U	U	U	U	1	1, 114,730	U	U	U	U	U	U

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2B - ANALYSIS OF CLAIMS UNPAID - PRIOR YEAR - NET OF REINSURANCE

	Claims Paid D	Ouring the Year	Claim Reserve au December 31 c		5	6
	1	2	3	4		Estimated Claim Reserve and Claim
Line of Business	On Claims Incurred Prior to January 1 of Current Year	On Claims Incurred During the Year	On Claims Unpaid December 31 of Prior Year	On Claims Incurred During the Year	Claims Incurred In Prior Years (Columns 1 + 3)	Liability December 31 of Prior Year
Comprehensive (hospital and medical) individual					0	0
Comprehensive (hospital and medical) group					0	0
3. Medicare Supplement					0	0
4. Vision Only					0	0
5. Dental Only					0	0
6. Federal Employees Health Benefits Plan					0	0
7. Title XVIII - Medicare	622, 154	6,258,078	242,091	872,645	864,245	1,358,310
8 Title XIX - Medicaid					0	0
9. Credit A&H					0	0
10. Disability Income					0	0
11. Long-Term Care					0	0
12. Other health					0	0
13. Health subtotal (Lines 1 to 12)		, - ,	242,091	, -		, , -
14. Health care receivables (a)		113,419			, ,	129, 100
15. Other non-health					0	0
16. Medical incentive pools and bonus amounts	92,033	98,942	6,232	97,379	98,265	53,270
17. Totals (Lines 13 - 14 + 15 + 16)	683,412	6,243,601	248,323	970,024	931,735	1,282,480

⁽a) Excludes \$ loans or advances to providers not yet expensed.

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (\$000 Omitted)

Section A - Paid Health Claims - Title XVIII

		Cumulative Net Amounts Paid					
		1	2	3	4	5	
	Year in Which Losses Were Incurred	2020	2021	2022	2023	2024	
1.	Prior	0	0	0	0	0	
2.	2020		0	0	0	0	
3.	2021	XXX	1,614	1,919	1,925	1,925	
4.	2022	XXX	XXX	6,979	7,430	7, 153	
5.	2023	XXX	xxx	XXX	6,717	7,677	
6.	2024	XXX	XXX	XXX	XXX	6,244	

Section B - Incurred Health Claims - Title XVIII

	Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonuse Outstanding at End of Year				
	1	2	3	4	5
Year in Which Losses Were Incurred	2020	2021	2022	2023	2024
1. Prior	0	0	0	0	0
2. 2020		0	0	0	0
3. 2021	XXX	1,839	1,914	1,926	1,925
4. 2022	XXX	XXX	7,882	7,472	7,394
5. 2023	XXX	XXX	XXX	8,086	7,684
6. 2024	XXX	XXX	XXX	XXX	7,214

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Title XVIII

	1	2	3	4	5	6	7	8	9	10
Years in which					Claim and Claim Adjustment Expense			Unpaid Claims	Total Claims and Claims Adjustment	
Premiums were Earned and Claims were Incurred	Premiums Earned	Claims Payment	Claim Adjustment Expense Payments	(Col. 3/2) Percent	Payments (Col. 2 + 3)	(Col. 5/1) Percent	Claims Unpaid	Adjustment Expenses	Expense Incurred (Col. 5+7+8)	(Col. 9/1) Percent
1. 2020		0	0	0.0	0	0.0	0	0	0	0.0
2. 2021	2,125	1,925	251	13.0	2,176	102.4	0	0	2,176	102.4
3. 2022	7.170	7.153		5.1	7.518	104.9	241	5	7.764	108.3
4. 2023	8.320	7,677	405	5.3	8.082	97.1	7	0	8.089	97.2
5. 2024	8,265	6,244	230	3.7	6,474	78.3	970	18	7,462	90.3

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (\$000 Omitted)

Section A - Paid Health Claims - Grand Total

		Cumulative Net Amounts Paid					
		1	2	3	4	5	
	Year in Which Losses Were Incurred	2020	2021	2022	2023	2024	
1.	Prior	0	0	0	0	0	
2.	2020	0	0	0	0	0	
3.	2021	XXX	1,614	1,919	1,925	1,925	
4.	2022	XXX	XXX	6,979	7,430	7, 153	
5.	2023	XXX	XXX	XXX	6,717	7,677	
6.	2024	XXX	XXX	XXX	XXX	6,244	

Section B - Incurred Health Claims - Grand Total

	Sum of Cumulative Net	Amount Paid and Claim Outs	Liability, Claim Resetanding at End of Ye	erve and Medical Incenti ar	ve Pool and Bonuses
	1	2	3	4	5
Year in Which Losses Were Incurred	2020	2021	2022	2023	2024
1. Prior	0	0	0	0	0
2. 2020	0	0	0	0	0
3. 2021	XXX	1,839	1,914	1,926	1,925
4. 2022	XXX	XXX	7,882	7,472	7,394
5. 2023	XXX	XXX	XXX	8,086	7,684
6. 2024	XXX	XXX	XXX	XXX	7,214

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Grand Total

		1	2	3	4	5	6	7	8	9	10
	Vanas in orbitals					Claim and Claim Adjustment Expense			Hanaid Olaina	Total Claims and	
	Years in which Premiums were Earned and Claims			Claim Adjustment	(Col. 3/2)	Payments	(Col. 5/1)		Unpaid Claims Adjustment	Claims Adjustment Expense Incurred	(Col. 9/1)
	were Incurred	Premiums Earned	Claims Payment	Expense Payments	Percent	(Col. 2 + 3)	Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
1.	2020	0	0	0	0.0	0	0.0	0	0	0	0.0
2.	2021	2,125	1,925	251	13.0	2,176	102.4	0	0	2,176	102.4
3.	2022	7,170	7, 153		5.1	7,518	104.9	241	5	7,764	108.3
4.	2023	8.320	7.677	405	5.3	8.082	97.1	7	0	8.089	97.2
5.	2024	8,265	6,244	230	3.7	6,474	78.3	970	18	7,462	90.3

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2D - AGGREGATE RESERVE FOR ACCIDENT AND HEALTH CONTRACTS ONLY

PART 2D - AGGREGATE RESERVE FOR ACCIDENT AND HEALTH CONTRACTS ONLY														
		1	Compret (Hospital 8		4	5	6	7	8	9	10	11	12	13
		Total	2 Individual	3 Group	Medicare Supplement	Vision Only	Dental Only	Federal Employees Health Benefits Plan	Title XVIII Medicare	Title XIX Medicaid	Credit A&H	Disability Income	Long-Term Care	Other
1.	Unearned premium reserves	n	marviduai	Отоир	Саррістісті	Vision Only	Dental Only	Deficited Figure	Wedleare	Wedledia	Orcall / Idi i	moonic	Guic	Other
2.	Additional policy reserves (a)	0				•••••				•••••				
3.														
4	Reserve for rate credits or experience rating refunds													
	(including \$ for investment income)	4,045							4.045					
5	Aggregate write-ins for other policy reserves				0	0	0		, -	0		0	0	0
6	Totals (gross)								4,045					
7.	Reinsurance ceded		U	0		U	0	0	4,045	0	0		0	
۷.	Totals (Net)(Page 3, Line 4)		0		0	0			4,045	0				
9.	Present value of amounts not yet due on claims	· ·					0	0	4,045	U	0	0	0	
10.	Reserve for future contingent benefits													
	Aggregate write-ins for other claim reserves			0	0	0				0				
	Totals (gross)			0			0		0	0	0	0	0	
13	Reinsurance ceded		0	0	0	0	0	0	0	0	0	0	0	0
14.	Totals (Net)(Page 3, Line 7)	0	0	0	0	0	0	0	0	0	0	0	0	0
.=	DETAILS OF WRITE-INS													
0501.														
0502.														
0503.														
0598.	Summary of remaining write-ins for Line 5 from overflow page	0	0	0	0	0	0	0	0	0	0	0	0	0
0599.	Totals (Lines 0501 through 0503 plus 0598) (Line 5 above)	0	0	0	0	0	0	0	0	0	0	0	0	0
1101.														
1102.														
1103.														
1198.	Summary of remaining write-ins for Line 11 from overflow page	0	0	0	0	0	0	0	0	0	0	0	0	0
1199.	Totals (Lines 1101 through 1103 plus 1198) (Line 11 above)	0	0	0	0	0	0	0	0	0	0	0	0	0

(a) Includes \$ premium deficiency reserve.

UNDERWRITING AND INVESTMENT EXHIBIT

PART 3 - ANALYSIS OF EXPENSES

		PART 3 - ANALY Claim Adjustme	YSIS OF EXPENSE	3 3	4	5
		1 Cost Containment Expenses	2 Other Claim Adjustment Expenses	General Administrative Expenses	Investment Expenses	Total
1.	Rent (\$ for occupancy of	Expende	Expended	Ехропосо	Ехроносс	rotar
	own building)	3 219	2 653	(1.071)		4 801
2.	Salary, wages and other benefits			158 , 183		
3.	Commissions (less \$					
Э.	ceded plus \$ assumed)	0		163 944		163 944
4.	Legal fees and expenses			, ,		,
5.	Certifications and accreditation fees					
6.	Auditing, actuarial and other consulting services					
7.	Traveling expenses			851		
8.	Marketing and advertising			102,699		ŕ
9.	Postage, express and telephone					•
	Printing and office supplies					
10.	Occupancy, depreciation and amortization					
11.	Equipment					
12.						009
13.	Cost or depreciation of EDP equipment and software	1,151	869	22,752		24,772
14.	Outsourced services including EDP, claims, and					
	other services					
15.	Boards, bureaus and association fees			405		
16.	Insurance, except on real estate					
17.	Collection and bank service charges					
18.	Group service and administration fees					
19.	Reimbursements by uninsured plans					0
20.	Reimbursements from fiscal intermediaries	0		0		0
21.	Real estate expenses	0	0	3,746		3,746
22.	Real estate taxes	0		280		280
23.	Taxes, licenses and fees:					
	23.1 State and local insurance taxes	0		22		22
	23.2 State premium taxes	0		0		0
	23.3 Regulatory authority licenses and fees	42	0	286		328
	23.4 Payroll taxes	7,307	3,824	8,818		19,949
	23.5 Other (excluding federal income and real estate taxes)	0		132		132
24.	Investment expenses not included elsewhere	0		0	9,436	9,436
25.	Aggregate write-ins for expenses	(397)	11,188	(15,524)	0	(4,733
26.	Total expenses incurred (Lines 1 to 25)	145,582	112,164	706,133	9,436	(a)973,315
27.	Less expenses unpaid December 31, current year		22,978	2,197		25 , 175
28.	Add expenses unpaid December 31, prior year	0	31,447	740	0	32 , 187
29.	Amounts receivable relating to uninsured plans, prior year	0	0	33,606	0	33,606
30.	Amounts receivable relating to uninsured plans, current year			535,272		535,272
31.	Total expenses paid (Lines 26 minus 27 plus 28 minus 29 plus 30)	145,582	120,633	1,206,342	9,436	1,481,993
	DETAILS OF WRITE-INS					
2501.	Miscellaneous expenses	(397)	11,188	(15,524)	0	(4,733
2502.						
2503.						
2598.	Summary of remaining write-ins for Line 25 from overflow page	0	0	0	0	0
	Totals (Lines 2501 through 2503 plus 2598)(Line 25 above) des management fees of \$	(397)	11, 188	(15,524)	0	(4,733

(a) Includes management fees of \$794,421 to affiliates and \$ to non-affiliates.

EXHIBIT OF NET INVESTMENT INCOME

		1	2
		Collected During Year	
1.	U.S. government bonds	(a) 0	0
1.1	Bonds exempt from U.S. tax		
1.2	Other bonds (unaffiliated)		
1.3	Bonds of affiliates	(a)0	0
2.1	Preferred stocks (unaffiliated)		
2.11	Preferred stocks of affiliates	(b) 0	0
2.2	Common stocks (unaffiliated)	0	0
2.21	Common stocks of affiliates	0	0
3.	Mortgage loans		
4.	Real estate	(d) 0	0
5	Contract Loans	0	0
6	Cash, cash equivalents and short-term investments	(e)620	620
7	Derivative instruments	(f)0	0
8.	Other invested assets	0	0
9.	Aggregate write-ins for investment income		
10.	Total gross investment income	117,298	
11.	Investment expenses		(g)
12.	Investment taxes, licenses and fees, excluding federal income taxes		
13.	Interest expense		(h)0
14.	Depreciation on real estate and other invested assets		(i)0
15.	Aggregate write-ins for deductions from investment income		0
16.	Total deductions (Lines 11 through 15)		9,436
17.	Net investment income (Line 10 minus Line 16)		109,362
	DETAILS OF WRITE-INS		
0901.	Miscellaneous income	116,649	116,649
0902.			
0903.			
0998.	Summary of remaining write-ins for Line 9 from overflow page	0	0
0999.	Totals (Lines 0901 through 0903 plus 0998) (Line 9, above)	116,649	116,649
1501.			
1502.			
1503.			
1598.	Summary of remaining write-ins for Line 15 from overflow page		0
1599.	Totals (Lines 1501 through 1503 plus 1598) (Line 15, above)		0
	ides \$	•	•
b) Inclu	ides \$ 0 accrual of discount less \$ 0 amortization of premium and less \$	paid for accrued div	vidends on purchases.

(b) Includes \$	0	occrual of discount less \$
(c) Includes \$	0	occrual of discount less \$ 0 amortization of premium and less \$
(d) Includes \$	0	for company's occupancy of its own buildings; and excludes \$
(e) Includes \$	0	occrual of discount less \$0 amortization of premium and less \$
(f) Includes \$	0	ccrual of discount less \$0 amortization of premium.
	0 and Separate Acco	nvestment expenses and \$
(h) Includes \$	0	nterest on surplus notes and \$ 0 interest on capital notes.
(i) Includes \$	0	depreciation on real estate and \$0 depreciation on other invested assets.

EXHIBIT OF CAPITAL GAINS (LOSSES)

		OI OAI I	.,,	<u> </u>	.	
		1	2	3	4	5
				T		
		Dealis at Oak (Leas)	Oller Deall and	Total Realized Capital	Change in	Change in Unrealized
		Realized Gain (Loss) On Sales or Maturity	Other Realized	Gain (Loss) (Columns 1 + 2)	Unrealized Capital	Foreign Exchange
		,	Adjustments	(Columns 1 + 2)	Gain (Loss)	Capital Gain (Loss)
1.	U.S. Government bonds					
1.1	Bonds exempt from U.S. tax					
1.2	Other bonds (unaffiliated)					
1.3	Bonds of affiliates					
2.1	Preferred stocks (unaffiliated)					
2.11	Preferred stocks of affiliates					
2.2	Common stocks (unaffiliated)					
2.21	Common stocks of affiliates					
3.	Mortgage loans					
4.	Real estate					
5.	Contract loans					
6.	Cash, cash equivalents and short-term investmen					
7.						
8.	Other invested assets					
9.	Aggregate write-ins for capital gains (losses)					
10.	Total capital gains (losses)					
10.	DETAILS OF WRITE-INS					
0901.	DETAILS OF WRITE-INS					
0902.						
0903.						
0998.	Summary of remaining write-ins for Line 9 from					
	overflow page					
0999.	Totals (Lines 0901 through 0903 plus 0998) (Line 9, above)					

EXHIBIT OF NON-ADMITTED ASSETS

	EXHIBIT OF NON-ADMITTE	1 Current Year Total Nonadmitted Assets	2 Prior Year Total Nonadmitted Assets	3 Change in Total Nonadmitted Assets (Col. 2 - Col. 1)
1.	Bonds (Schedule D)			0
2.	Stocks (Schedule D):			
	2.1 Preferred stocks			0
	2.2 Common stocks			0
3.	Mortgage loans on real estate (Schedule B):			
	3.1 First liens			0
	3.2 Other than first liens			
4.	Real estate (Schedule A):			
••	4.1 Properties occupied by the company			0
	4.2 Properties held for the production of income			
	4.3 Properties held for sale			_
5.	Cash (Schedule E - Part 1), cash equivalents (Schedule E - Part 2) and short-term investments (Schedule DA)			
6.	Contract loans			0
7.	Derivatives (Schedule DB)			0
8.	Other invested assets (Schedule BA)			0
9.	Receivables for securities			
10.	Securities lending reinvested collateral assets (Schedule DL)			
11.	Aggregate write-ins for invested assets			
12.	Subtotals, cash and invested assets (Lines 1 to 11)			
13.	Title plants (for Title insurers only)			
14.	Investment income due and accrued			
15.	Premiums and considerations:	,-	, -	
10.	15.1 Uncollected premiums and agents' balances in the course of collection	15 431	2 800	(12 631)
	15.2 Deferred premiums, agents' balances and installments booked but deferred and not yet due			
	15.3 Accrued retrospective premiums and contracts subject to redetermination			
16.	Reinsurance:			
10.	16.1 Amounts recoverable from reinsurers		0	0
	16.2 Funds held by or deposited with reinsured companies			
	16.3 Other amounts receivable under reinsurance contracts			
17	Amounts receivable relating to uninsured plans			
	Current federal and foreign income tax recoverable and interest thereon			
18.1				
	Net deferred tax asset			0
19.	Guaranty funds receivable or on deposit			0
20.	Electronic data processing equipment and software			0
21.	Furniture and equipment, including health care delivery assets			0
22.	Net adjustment in assets and liabilities due to foreign exchange rates			0
23.	Receivable from parent, subsidiaries and affiliates			0
24.	Health care and other amounts receivable			
25.	Aggregate write-ins for other-than-invested assets	210	0	(210)
26.	Total assets excluding Separate Accounts, Segregated Accounts and Protected Cell Accounts (Lines 12 to 25)			
27.	From Separate Accounts, Segregated Accounts and Protected Cell Accounts		70 542	0
28.	Total (Lines 26 and 27)	76,115	78,543	2,428
1101.	DETAILS OF WRITE-INS			
1102.				
1103.				
1198.	Summary of remaining write-ins for Line 11 from overflow page	0	0	0
1199.	Totals (Lines 1101 through 1103 plus 1198)(Line 11 above)	0	0	0
2501.	Prepaid expenses	210	0	(210)
2502.				
2503.				
2598.	Summary of remaining write-ins for Line 25 from overflow page	0	0	0
2599.	Totals (Lines 2501 through 2503 plus 2598)(Line 25 above)	210	0	(210)

17

EXHIBIT 1 - ENROLLMENT BY PRODUCT TYPE FOR HEALTH BUSINESS ONLY

			Total Members at End of			6
Source of Enrollment	1 Prior Year	2 First Quarter	3 Second Quarter	4 Third Quarter	5 Current Year	Current Year Member Months
Health Maintenance Organizations						
2. Provider Service Organizations						
Preferred Provider Organizations		733		737	749	8,858
4. Point of Service						
5. Indemnity Only						
Aggregate write-ins for other lines of business	0	0	0	0	0	0
7. Total	905	733	732	737	749	8,858
DETAILS OF WRITE-INS						
0601.						
0602.						
0603.						
0698. Summary of remaining write-ins for Line 6 from overflow page	0	0	0	0	0	0
0699. Totals (Lines 0601 through 0603 plus 0698) (Line 6 above)	0	0	0	0	0	0

1. Summary of Significant Accounting Policies and Going Concern

A. Accounting Practices

The accompanying financial statements of AMH Health Plans of Maine, Inc. (the "Company") have been prepared in conformity with the National Association of Insurance Commissioners' ("NAIC") *Annual Statement Instructions* and in accordance with accounting practices prescribed by the NAIC *Accounting Practices and Procedures Manual* ("NAIC SAP"), subject to any deviations prescribed or permitted by the Bureau.

A reconciliation of the Company's net income (loss) and capital and surplus between NAIC SAP and practices prescribed and permitted by the Bureau is shown below:

		SSAP#	F/S Page	F/S Line #	2024	2023
Net	Income					
(1)	AMH Health Plans of Maine, Inc state basis (Page 4, Line 32, Columns 2 & 3)	XXX	XXX	XXX	\$ 1,499,395	\$ 181,704
(2)	State Prescribed Practices that is an increase/(decrease) from NAIC SAP:					
(3)	State Permitted Practices that is an increase/(decrease) from NAIC SAP:					
(4)	NAIC SAP (1-2-3=4)	XXX	XXX	XXX	\$ 1,499,395	\$ 181,704
<u>Sur</u>	<u>plus</u>					
(5)	AMH Health Plans of Maine, Inc state basis (Page 3, Line 33, Columns 3 & 4)	XXX	XXX	XXX	\$ 5,392,398	\$ 3,890,575
(6)	State Prescribed Practices that is an increase/(decrease) from NAIC SAP:					
(7)	State Permitted Practices that is an increase/(decrease) from NAIC SAP:					
(8)	NAIC SAP (5-6-7=8)	XXX	XXX	XXX	\$ 5,392,398	\$ 3,890,575

B. Use of Estimates in the Preparation of the Financial Statements

Preparation of financial statements requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.

C. Accounting Policies

Health premiums are earned over the term of the related insurance policies. Premiums written are reported net of experience rating refunds. Premiums paid prior to the effective date are recorded on the balance sheet as premiums received in advance and are subsequently credited to income as earned during the coverage period. Premium rates are subject to approval by the Centers for Medicare and Medicaid Services. Expenses are charged to operations as incurred.

In addition, the Company uses the following accounting policies:

- (1) Short-term investments include investments with maturities of less than one year and more than three months at the date of acquisition and are reported at amortized cost, which approximates fair value. Non-investment grade short-term investments are stated at the lower of amortized cost or fair value.
- (2) Investment grade bonds not backed by other loans are stated at amortized cost, with amortization calculated based on the modified scientific method, using lower of yield to call or yield to maturity. Non-investment grade bonds are stated at the lower of amortized cost or fair value as determined by various third-party pricing sources.
- (3) The Company has no investments in common stocks of unaffiliated companies.
- (4) The Company has no investments in preferred stocks.
- (5) The Company has no investment in residual tranche bonds and preferred stocks.
- (6) The Company has no mortgage loans real estate.
- (7) The Company has no loan-backed securities.
- (8) The Company has no investments in subsidiaries, controlled and affiliated companies.
- (9) The Company has no investments in joint ventures, partnerships or limited liability companies.
- (10) The Company has no derivative instruments.
- (11) The Company recognizes losses from other-than-temporary impairments ("OTTI") of investments in accordance with Statements of Standard Accounting Practice ("SSAP") No. 26, *Bonds*; and SSAP No. 30, *Common Stock*; and SSAP No. 32, *Preferred Stock*.
- (12) The Company does not anticipate investment income as a factor in premium deficiency calculations.
- (13) Unpaid claims and claims adjustment expenses include management's best estimate of amounts based on historical claim development patterns and certain individual case estimates. The established liability considers health benefit provisions, business practices, economic conditions and other factors that may materially affect the cost, frequency and severity of claims. Liabilities for unpaid claims and claim adjustment expenses are based on assumptions and estimates, and while management believes such estimates are reasonable, the ultimate liability may be in excess of or less than the amount provided. The methods for making such estimates and for establishing the resulting liabilities are continually reviewed and changes in estimates are incorporated into current period estimates.
- (14) The Company has not modified its capitalization policy from the prior period.
- (15) Pharmacy rebate receivables are recorded when earned based upon actual rebate receivables billed and an estimate of receivables based upon current utilization of specific pharmaceuticals and provider contract terms.

D. Going Concern

Not applicable.

2. Accounting Changes and Corrections of Errors

There were no accounting changes or corrections of errors during the years ended December 31, 2024 and 2023.

3. Business Combinations and Goodwill

A. Statutory Purchase Method

Not applicable.

B. Statutory Merger

Not applicable.

C. Assumption Reinsurance

Not applicable.

D. Impairment Loss

Not applicable.

E. Subcomponents and Calculation of Adjusted Surplus and Total Admitted Goodwill

Not applicable.

4. Discontinued Operations

The Company had no operations that were discontinued during 2024 or 2023.

5. Investments

A. Mortgage Loans, including Mezzanine Real Estate Loans

The Company did not have investments in mortgage loans at December 31, 2024 or 2023.

B. Debt Restructuring

The Company did not have invested assets that were restructured debt at December 31, 2024 or 2023.

C. Reverse Mortgages

The Company did not have investments in reverse mortgages at December 31, 2024 or 2023.

D. Loan-Backed Securities

- (1) The Company did not have loan-backed securities at December 31, 2024 and 2023.
- (2) The Company did not recognize OTTI on its loan-backed securities during the years ended December 31, 2024 and 2023.
- (3) The Company did not recognize OTTI on its loan-backed securities at December 31, 2024 and 2023.
- (4) The Company had no impaired loan-backed securities for which an OTTI had not been recognized in earnings at December 31, 2024 and 2023.
- (5) The Company had no impaired loan-backed securities at December 31, 2024 and 2023.

NOTES TO FINANCIAL STATEMENTS

E. Dollar Repurchase Agreements and/or Securities Lending Transactions

The Company did not enter into repurchase agreements or securities lending transactions at December 31, 2024 or 2023.

F. Repurchase Agreements Transactions Accounted for as Secured Borrowing

The Company did not enter into repurchase agreement transactions accounted for as secured borrowing at December 31, 2024 or 2023.

G. Reverse Repurchase Agreements Transactions Accounted for as Secured Borrowing

The Company did not enter into reverse repurchase agreement transactions accounted for as a secured borrowing at December 31, 2024 or 2023.

H. Repurchase Agreements Transactions Accounted for as a Sale

The Company did not enter into repurchase agreement transactions accounted for as a sale at December 31, 2024 or 2023.

I. Reverse Repurchase Agreements Transactions Accounted for as a Sale

The Company did not enter into reverse repurchase agreement transactions accounted for as a sale at December 31, 2024 or 2023.

J. Real Estate

The Company did not have investments in real estate and did not engage in retail land sales operations during 2024 or 2023.

K. Investments in Low-Income Housing Tax Credits

The Company did not invest in properties generating low-income housing tax credits during 2024 or 2023.

L. Restricted Assets

(1) Restricted assets (including pledged)

		1	2	3	4	5	6	7
Re	stricted Asset Category	Total Gross (Admitted & Nonadmitted) Restricted from Current Year	Total Gross (Admitted & Nonadmitted) Restricted from Prior Year	Increase/ (Decrease) (1 minus 2)	Total Current Year Nonadmitted Restricted	Total Current Year Admitted Restricted (1 minus 4)	Gross Admitted and Nonadmitted Restricted to Total Assets (a)	Admitted Restricted to Total Admitted Assets (b)
a.	Subject to contractual obligation for which liability is not shown	\$ —	\$ —	\$ —	\$ —	\$ —	0.00 %	0.00 %
b.	Collateral held under security lending agreements	_	_	_	_	_	0.00 %	0.00 %
c.	Subject to repurchase agreements	_	_	_	_	_	0.00 %	0.00 %
d.	Subject to reverse repurchase agreements	_	_	_	_	_	0.00 %	0.00 %
e.	Subject to dollar repurchase agreements	_	_	_	_	_	0.00 %	0.00 %
f.	Subject to dollar reverse repurchase agreements	_	_	_	_	_	0.00 %	0.00 %
g.	Placed under option contracts	_	_	_	_	_	0.00 %	0.00 %
h.	Letter stock or securities restricted as to sale-excluding FHLB capital stock	_	_	_	_	_	0.00 %	0.00 %
i.	FHLB capital stock	_	_	_	_	_	0.00 %	0.00 %
j.	On deposit with states	116,581	118,552	(1,971)	_	116,581	1.59 %	1.61 %
k.	On deposit with other regulatory bodies	_	_	_		_	0.00 %	0.00 %
1.	Pledged as collateral to FHLB (including assets backing funding agreements)	_	_	_	_	_	0.00 %	0.00 %
m.	Pledged as collateral not captured in other categories	_	_	_	_	_	0.00 %	0.00 %
n.	Other restricted assets	_	_	_	_	_	0.00 %	0.00 %
0.	Total Restricted Assets	\$ 116,581	\$ 118,552	\$ (1,971)	s —	\$ 116,581	1.59 %	1.61 %

⁽a) Column 1 divided by Asset Page, Column 1, Line 28

- (2) Not applicable.
- (3) Not applicable.
- (4) Not applicable.

M. Working Capital Finance Investments

The Company did not have any working capital finance investments at December 31, 2024 and 2023.

N. Offsetting and Netting of Assets and Liabilities

The Company did not have any offsetting or netting of assets and liabilities at December 31, 2024 and 2023.

O. 5GI Securities

The Company has no 5GI Securities as of December 31, 2024 and 2023.

P. Short Sales

The Company did not have any short sales at December 31, 2024 and 2023.

⁽b) Column 5 divided by Asset Page, Column 3, Line 28

Q. Prepayment Penalty and Acceleration Fees

The Company did not have any prepayment penalty or acceleration fees at December 31, 2024 and 2023

R. Reporting Entity's Share of Cash Pool by Asset Type

The Company did not participate in a cash pool at December 31, 2024 or 2023.

S. Aggregate Collateral Loans by Qualifying Investment Collateral

The Company did not have any aggregate collateral loans with qualifying investment collateral at December 31, 2024 or 2023.

6. Joint Ventures, Partnerships and Limited Liability Companies

- **A.** The Company has no investments in joint ventures, partnerships, or LLCs.
- **B.** Not applicable.

7. Investment Income

- **A.** All investment income due and accrued with amounts that are over 90 days past due is non-admitted.
- **B.** At December 31, 2024 and 2023 there was \$1,500 and \$1,500 of nonadmitted accrued investment income, respectively.
- C. At December 31, 2024 and 2023 the gross, nonadmitted and admitted amounts for interest income due and accrued are as follows:

Interest Income Due and Accrued	2024	20)23
1. Gross	\$ 2,375	\$	2,375
2. Nonadmitted	\$ 1,500	\$	1,500
3. Admitted	\$ 875	\$	875

- **D**. At December 31, 2024 and 2023 the Company had no aggregate deferred interest.
- E. At December 31, 2024 and 2023, the Company had no cumulative amounts of paid-in-kind ("PIK") interest included in the current principal balance.

8. Derivative Instruments

The Company has no derivative instruments.

9. Income Taxes

A. The components of net deferred tax assets (liabilities):

(1) The components of net deferred tax asset (liabilities) are as follows:

			12/31/2024	
		(1)	(2)	(3)
		Ordinary	Capital	(Col 1+2) Total
(a) (b)	Gross Deferred Tax Assets Statutory Valuation Allowance Adjustments	\$ 652,718 652,718	\$ —	\$ 652,718 652,718
(c)	Adjusted Gross Deferred Tax Assets (1a - 1b)	032,710		032,718
(d)	Deferred Tax Assets Nonadmitted			
(e)	Subtotal Net Admitted Deferred Tax Asset (1c - 1d)			
(f)	Deferred Tax Liabilities		_	_
(g)	Net Admitted Deferred Tax Asset/(Net Deferred Tax Liability) (1e - 1f)	\$ _	\$ —	\$ —
			12/31/2023	
		(4)	(5)	(6)
		Ordinary	Capital	(Col 4+5) Total
(a)	Gross Deferred Tax Assets	\$ 968,346	s —	\$ 968,346
(b)	Statutory Valuation Allowance Adjustments	968,346		968,346
(c)	Adjusted Gross Deferred Tax Assets (1a - 1b)		_	
(d)	Deferred Tax Assets Nonadmitted	_	_	_
(e)	Subtotal Net Admitted Deferred Tax Asset (1c - 1d)	_	_	_
(f)	Deferred Tax Liabilities		_	_
(g)	Net Admitted Deferred Tax Asset/(Net Deferred Tax Liability) (1e - 1f)	<u>\$</u>	\$ —	\$ —
			Change	
			(4)	100

		()	()		i `´	
		(Col 1-4) Ordinary	(Col 2-: Capita	,	(Col 7+8) Total	
(a)	Gross Deferred Tax Assets	\$ (315,628)	\$	— \$	(315,628)	
(b)	Statutory Valuation Allowance Adjustments	(315,628)			(315,628)	
(c)	Adjusted Gross Deferred Tax Assets (1a - 1b)	_		_	_	
(d)	Deferred Tax Assets Nonadmitted	_			_	
(e)	Subtotal Net Admitted Deferred Tax Asset (1c - 1d)	_			_	
(f)	Deferred Tax Liabilities	_			_	
(g)	Net Admitted Deferred Tax Asset/(Net Deferred Tax Liability) (1e - 1f)	\$ 	\$	— \$		

(2) The amount of admitted adjusted gross deferred tax assets under each component of SSAP No. 101, *Income Taxes* ("SSAP No. 101") are as follows:

12/31/2024			
(1)	(2)	(3)	
Ordinary	Capital	(Col 1+2) Total	

Admission Calculation Components SSAP No. 101

- (a) Federal Income Taxes Paid in Prior Years Recoverable Through Loss Carrybacks.
- (b) Adjusted Gross Deferred Tax Assets Expected To Be Realized (Excluding The Amount Of Deferred Tax Assets From 2(a) above) After Application of the Threshold Limitation. (The Lesser of 2(b)1 and 2(b)2 Below)
 - 1. Adjusted Gross Deferred Tax Assets Expected To Be Realized Following the Balance Sheet Date.
 - Adjusted Gross Deferred Tax Assets Allowed per Limitation Threshold.
- (c) Adjusted Gross Deferred Tax Assets (Excluding The Amount Of Deferred Tax Assets From 2(a) and 2(b) above) Offset by Gross Deferred Tax Liabilities.
- (d) Deferred Tax Assets Admitted as the result of application of SSAP No. 101. Total (2(a) + 2(b) + 2(c))

	\$ — \$	— \$	
	_	_	_
	_	_	_
l	XXX	XXX	808,860
f			
-			
	\$ — \$	<u> </u>	

	12/31/2023	
(4)	(5)	(6)
Ordinary	Capital	(Col 4+5) Total

Admission Calculation Components SSAP No. 101

- (a) Federal Income Taxes Paid in Prior Years Recoverable Through Loss Carrybacks.
- (b) Adjusted Gross Deferred Tax Assets Expected To Be Realized (Excluding The Amount Of Deferred Tax Assets From 2(a) above) After Application of the Threshold Limitation. (The Lesser of 2(b)1 and 2(b)2 Below)
 - 1. Adjusted Gross Deferred Tax Assets Expected To Be Realized Following the Balance Sheet Date.
 - 2. Adjusted Gross Deferred Tax Assets Allowed per Limitation Threshold.
- (c) Adjusted Gross Deferred Tax Assets (Excluding The Amount Of Deferred Tax Assets From 2(a) and 2(b) above) Offset by Gross Deferred Tax Liabilities.
- (d) Deferred Tax Assets Admitted as the result of application of SSAP No. 101. Total (2(a) + 2(b) + 2(c))

\$ — \$	— \$	_
	_	_
_	_	_
XXX	XXX	583,586
\$ — \$	<u> </u>	

Change				
(7)	(8)	(9)		
(Col 1-4) Ordinary	(Col 2-5) Capital	(Col 7+8) Total		

Admission Calculation Components SSAP No. 101

- (a) Federal Income Taxes Paid in Prior Years Recoverable Through Loss Carrybacks.
- (b) Adjusted Gross Deferred Tax Assets Expected To Be Realized (Excluding The Amount Of Deferred Tax Assets From 2(a) above) After Application of the Threshold Limitation. (The Lesser of 2(b)1 and 2(b)2 Below)
 - 1. Adjusted Gross Deferred Tax Assets Expected To Be Realized Following the Balance Sheet Date.
 - 2. Adjusted Gross Deferred Tax Assets Allowed per Limitation Threshold.
- (c) Adjusted Gross Deferred Tax Assets (Excluding The Amount Of Deferred Tax Assets From 2(a) and 2(b) above) Offset by Gross Deferred Tax Liabilities.
- (d) Deferred Tax Assets Admitted as the result of application of SSAP No. 101. Total (2(a) + 2(b) + 2(c))

\$ — \$	- \$	_
_		_
_	_	_
XXX	XXX	225,274
\$ — \$	— \$	_

(3)									2024		20)23	
	(a)	Ra Th	tio Percentage Used To Det reshold Limitation Amount	ermine Re	cover	ry Period A	and		696.8	8 %		502	2.17 %
	(b)	De	nount Of Adjusted Capital A stermine Recovery Period A b)2 Above.	And Surplo nd Thresh	ıs Use old Li	ed To imitation I	n	\$	5,392,39	8 \$	S 3,	,890,	,575
(4)				12	/31/20	024		12/31	/2023		Cha	nge	
				(1)		(2)		(3)	(4)		(5)		(6)
				Ordinan	y	Capital	0:	rdinary	Capita		Col 1-3) Ordinary		ol 2-4) apital
	Imp	act	of Tax-Planning Strategies										
	(a)	Gro and Tax	termination of Adjusted oss Deferred Tax Assets I Net Admitted Deferred x Assets, By Tax aracter As A Percentage.										
		1.	Adjusted Gross DTAs Amount From Note 9A1(c)	\$ —	\$	_	\$	_	\$ —	\$	_	\$	_
		2.	Percentage of Adjusted Gross DTAs By Tax Character Attributable To The Impact Of Tax Planning Strategies	0.00	%	0.00 %		0.00 %	0.00	%	0.00 %		0.00 %
		3.	Net Admitted Adjusted Gross DTAs Amount From Note 9A1(e)	\$ —	\$	_	\$	_	\$ —	\$	_	\$	_
		4.	Percentage of Net Admitted Adjusted Gross DTAs By Tax Character Admitted Because Of The Impact Of Tax Planning Strategies	0.00	%	0.00 %		0.00 %	0.00	%	0.00 %		0.00 %
	(b)	Do	es the Company's tax-plann of reinsurance?	ing strateg	gies in	iclude the	Ye	es		No	0		X

B. The Company has no unrecognized deferred tax liabilities at December 31, 2024 and 2023.

C. Current income taxes incurred consist of the following major components:

		(1)	(2)	(3)
		12/31/2024	12/31/2023	(Col 1-2) Change
(1) Cur	rent Income Tax			
(a)	Federal	\$ —	\$ —	\$ —
(b)	Foreign		_	
(c)	Subtotal		_	
(d)	Federal income tax expense on net capital gains		_	_
(e)	Utilization of capital loss carry-forwards			
(f)	Other			
(g)	Federal and foreign income taxes incurred	\$ —	\$ —	\$ —

			(1)	(2)	(3)
			12/31/2024	12/31/2023	(Col 1-2) Change
(2)	Def	erred Tax Assets:	12/01/2021	12/01/2020	Chunge
,	(a)	Ordinary			
		(1) Discounting of unpaid losses	\$ 3,527	\$ 4,256	\$ (729)
		(2) Unearned premium reserve	46	216	(170)
		(3) Policyholder reserves	_	_	_
		(4) Investments			_
		(5) Deferred acquisition costs	_		_
		(6) Policyholder dividends accrual			_
		(7) Fixed assets		71	(71)
		(8) Compensation and benefits accrual			_
		(9) Pension accrual			_
		(10) Receivables - nonadmitted	15,625	16,179	(554)
		(11) Net operating loss carry-forward	619,586	742,217	(122,631)
		(12) Tax credit carry-forward			(122,001)
		(13) Other	13,934	205,407	(191,473)
		(99) Subtotal (sum of 2a1 through 2a13)	652,718	968,346	(315,628)
	(b)	Statutory valuation allowance adjustment	652,718	968,346	(315,628)
	` ′	Nonadmitted	032,710	700,540	(313,020)
	(c)	Admitted ordinary deferred tax assets (2a99 - 2b - 2c)			
	(d) (e)	Capital	_		_
	(6)	Сарна		_	_
		(1) Investments	_	_	_
		(2) Net capital loss carry-forward	_		_
		(3) Real estate	_	_	_
		(4) Other			
		(99) Subtotal (2e1+2e2+2e3+2e4)	_		_
	(f)	Statutory valuation allowance adjustment			_
	(g)	Nonadmitted	_	_	_
	(h)	Admitted capital deferred tax assets (2e99 - 2f - 2g)	_		
	(i)	Admitted deferred tax assets (2d + 2h)	\$	\$ —	\$
	(1)	Admitted deferred tax assets (2d + 2ii)	Ψ	ψ	Ψ
(3)		erred Tax Liabilities:			
	(a)	Ordinary			
		(1) Investments	\$ —	\$ —	\$ —
		(2) Fixed assets			
		(3) Deferred and uncollected premium			_
		(4) Policyholder reserves			
		(5) Other			
		(99) Subtotal (3a1+3a2+3a3+3a4+3a5)	_		
	(b)	Capital			
		(1) Investments	_	_	_
		(2) Real estate	_		_
		(3) Other			
		(99) Subtotal (3b1+3b2+3b3)	_	_	
	(c)	Deferred tax liabilities (3a99 + 3b99)			
(4)	Net	deferred tax assets/liabilities (2i - 3c)	\$ —	\$ —	\$

D. The Company's income tax expense and change in deferred income taxes differs from the amount obtained by applying the federal statutory income tax rate of 21% for the year ended December 31 as follows:

	2024	2023
Tax expense computed using federal statutory rate	\$ 314,873 \$	38,158
Change in nonadmitted assets	510	(8,506)
Tax exempt income and dividend received deduction net of proration	(240)	(195)
Prior year true-up and adjustments	485	
Valuation allowance	(315,628)	(29,457)
Total	\$ — \$	
Federal income taxes incurred	\$ \$	_
Change in net deferred income taxes	 _	
Total statutory income taxes	\$ — \$	

E. Operating loss carryforwards:

(1) At December 31, 2024, the Company had the following unused net operating loss or corporate alternative minimum tax ("AMT") credit carryforwards available to offset future taxable income. The losses or credits will begin to expire as noted.

	Unused NOL Carryforwards	Origination Date	Expiration Date	Unused Corporate AMT Credit Carryforwards	Origination Date	Expiration Date	
Ī	2,950,411	2020	2043	\$ _			

- (2) The Company has no federal income taxes available for recoupment.
- (3) The Company has no protective tax deposits reported as admitted assets under Section 6603 of the Internal Revenue Service Code as of December 31, 2024 and 2023.
- **F.** The Company's Federal Income Tax return is a separate filing. No owner has the required 80% to include them in a consolidated return. Thus, no tax sharing agreement is in place for federal income taxes. As of December 31, 2024, the statute of limitations of the 2024, 2023, 2022 and 2021 tax years remain open.
- G. Not applicable.
- H. Repatriation Transition Tax (RTT)

Not applicable.

I. Alternative Minimum Tax (AMT) Credit

- (1) On August 16, 2022, the U.S. government enacted the Inflation Reduction Act which includes a new corporate AMT of 15% on the adjusted financial statement of income ("AFSI") of corporations with average AFSI exceeding \$1.0 billion over a three-year period. The corporate AMT is effective beginning after December 31, 2022. The Company has determined that it is not an applicable corporation, therefore it does not expect to be subject to the corporate AMT in 2024.
- (2) Does the Company's tax-planning strategies include the use of corporate AMT? Yes No \underline{X}

10. Information Concerning Parent, Subsidiaries, Affiliates and Other Related Parties

A. Nature of the Relationship

The Company is a Maine domiciled stock insurance company and is a wholly-owned subsidiary of AMH Health, LLC ("AMH"), which is owned 50% by Anthem Partnership Holding Company ("APHC"), which is an indirect wholly-owned subsidiary of Elevance Health, a publicly traded company and 50% by Maine Health, a not-for-profit corporation with hospitals, providers, and healthcare organizations primarily located in Maine.

B. Significant Transactions for Each Period

There were no significant transactions during the years ended December 31, 2024 and 2023.

For changes to the intercompany management and service arrangements see Note 10E. The amounts of transactions under such agreements are presented in Schedule Y, Part 2.

C. Transactions with Related Parties who are not Reported on Schedule Y

The Company has no transactions with related parties who are not reported on Schedule Y

D. Amounts Due to or from Related Parties

At December 31, 2024, the Company reported no amounts due from affiliates. At December 31, 2024, the Company reported \$575,985 due to affiliates. At December 31, 2023, the Company reported \$615,595 due from affiliates. At December 31, 2023, the Company reported no amounts due to affiliates. The receivable and payable balances represent intercompany transactions that will be settled in accordance with the settlement terms of the intercompany agreement.

E. Management and Service Contracts and Cost Sharing Arrangements

The Company has entered into administrative services agreements with its affiliated companies. Pursuant to these agreements, various administrative, management and support services are provided to or provided by the Company. The costs and expenses related to these administrative management and support services are allocated to or allocated by the Company in an amount equal to the direct and indirect costs and expenses incurred in providing these services. Costs include expenses such as salaries, employee benefits, information technology, pharmacy benefits administration, dental benefits management services, health care management services, communications, advertising, consulting services, rent, utilities, billing, accounting, underwriting, and product development, which support the Company's operations. These costs are allocated based on various utilization statistics.

F. Guarantees or Contingencies for Related Parties

The Company did not enter into guarantees or undertakings for the benefit of an affiliate which would result in a material contingent exposure of the Company's or any affiliated insurer's assets or liabilities.

G. Nature of Control Relationships that Could Affect Operations or Financial Position

AMH owns all outstanding shares of the Company.

H. Amount Deducted for Investment in Upstream Company

The Company does not own shares of upstream intermediate entities or Elevance Health.

I. Detail of Investments in Affiliates Greater than 10% of Admitted Assets

At December 31, 2024 and 2023, the Company did not have investments in affiliates.

J. Write-down for Impairments of Investments in Subsidiaries, Controlled or Affiliated ("SCA") Companies

Not applicable.

K. Investment in a Foreign Insurance Subsidiary

The Company does not have investments in foreign insurance subsidiaries.

L. Investment in Downstream Non-insurance Holding Companies

The Company does not have investments in downstream non-insurance holding companies.

M. All SCA Investments

The Company has no SCA Investments.

N. Investment in Insurance SCAs

The Company does not have investments in Insurance SCAs.

O. SCA or SSAP 48 Entity Loss Tracking

The Company does not have losses on investments in Insurance SCAs and/or joint ventures, partnerships or LLCs.

11. Debt

A. Capital Notes and Other Debt

The Company had no capital notes or other debt outstanding at December 31, 2024 and 2023.

B. FHLB (Federal Home Loan Bank) Agreements

The Company had no FHLB agreements outstanding at December 31, 2024 and 2023.

C. All Other Debt

The Company had no other debt outstanding at December 31, 2024 and 2023.

12. Retirement Plans, Deferred Compensation, Postemployment Benefits and Compensated Absences and Other Postretirement Benefit Plans

A. Defined Benefit Plan

Not applicable - See Note 12G.

B. Not applicable - See Note 12G.

- C. Not applicable See Note 12G.
- **D.** Not applicable See Note 12G.

E. Defined Contribution Plans

Not applicable - See Note 12G.

F. Multiemployer Plans

The Company does not participate in a multiemployer plan.

G. Consolidated/Holding Company Plans

The Company participates in the Elevance Health 401(k) Plan, sponsored by ATH Holding Company, LLC ("ATH Holding") and covering substantially all employees. Voluntary employee contributions are matched by ATH Holding subject to certain limitations. ATH Holding allocates a share of the total accumulated costs of this plan to the Company based on the number of allocated employees. The Company has no legal obligation for benefits under this plan.

The Company participates in a stock incentive compensation plan, sponsored by Elevance Health, providing incentive awards to non-employee directors and employees, consisting of Elevance Health stock options, restricted stock, restricted stock units, stock appreciation rights, performance shares, and performance units. Elevance Health allocates a share of the total share-based compensation expense of this plan to the Company based on the number of allocated employees. The Company has no legal obligation for benefits under this plan.

During 2024 and 2023, the Company was allocated the following costs or (credits) for these retirement benefits:

	2024	2023
Defined contribution plan	10,593	15,067
Stock incentive compensation plan	7,869	8,754

H. Post Employment Benefits and Compensated Absences

Not applicable.

I. Impact of Medicare Modernization Act on Postretirement Benefits (INT 04-17)

Not applicable.

13. Capital and Surplus, Shareholders' Dividend Restrictions and Quasi-Reorganizations

A. Outstanding Shares

As of December 31, 2024, the Company has 1,000,000 shares of \$1 par value common stock authorized, issued and outstanding.

B. Preferred Stock

The Company has no preferred stock outstanding.

C. Dividend Restrictions

Under Maine law, the Company is limited in the amount of dividends that can be declared without regulatory approval. The Superintendent of Insurance must approve any dividend that, together with all dividends declared during the preceding twelve months,

exceeds the greater of the net gain from operations for the twelve-month period ending December 31 of the preceding year or 10% of the Company's surplus to policyholders as of December 31 of the preceding year as long as unassigned surplus is positive. Also, any dividend paid from other than unassigned funds will need the approval of the Superintendent of Insurance.

D. Dividends Paid

See Footnote 10B.

E. Maximum Ordinary Dividend During 2023

Within the limitations of (C) above, the Company may not pay dividends during 2025 without prior approval.

F. Unassigned Surplus Restrictions

Unassigned surplus funds are not restricted at December 31, 2024.

G. Mutual Surplus Advances

Not applicable.

H. Company Stock Held for Special Purpose

There are no shares of stock held for special purposes at December 31, 2024.

I. Changes in Special Surplus Funds

There are no special surplus funds at December 31, 2024.

J. Changes in Unassigned Funds

There was no portion of unassigned funds represented by cumulative unrealized investment gains and losses at December 31, 2024.

K. Surplus Notes

The Company has not issued any surplus notes or debentures or similar obligations.

L. Restatement due to Prior Quasi-reorganizations

The Company had no restatements due to prior quasi-reorganizations.

M. Quasi-reorganizations over Prior 10 Years

The Company has not been involved in a quasi-reorganization during the past 10 years.

14. Liabilities, Contingencies and Assessments

A. Contingent Commitments

The Company had no contingent commitments at December 31, 2024 or 2023.

B. Assessments

- (1) The Company is subject to guaranty fund and other assessments by the state(s) in which it writes business. Guaranty fund assessments are accrued at the time of covered insurer insolvencies. Other assessments are accrued at the time the assessment obligation is incurred.
- (2) Not applicable.
- (3) Not applicable.

C. Gain Contingencies

The Company has no gain contingencies at December 31, 2024 or 2023.

D. Claims-Related Extra Contractual Obligation and the Bad Faith Losses Stemming From Lawsuits

Not applicable.

E. Joint and Several Liabilities

Not applicable.

F. All Other Contingencies

Other Contingencies

From time to time, the Company and certain of its subsidiaries are parties to various legal proceedings, many of which involve claims for coverage encountered in the ordinary course of business. The Company, like Health Maintenance Organizations ("HMOs") and health insurers generally, exclude certain healthcare and other services from coverage under their HMO, Preferred Provider Organizations and other plans. The Company is, in the ordinary course of business, subject to the claims of their enrollees arising out of decisions to restrict or deny reimbursement for uncovered services. The loss of even one such claim, if it results in a significant punitive damage award, could have a material adverse effect on the Company. In addition, the risk of potential liability under punitive damage theories may increase significantly the difficulty of obtaining reasonable reimbursement of coverage claims.

The Company is involved in pending and threatened litigation of the character incidental to the business transacted, arising out of its operations and is from time to time involved as a party in various governmental investigations, audits, reviews and administrative proceedings. These investigations, audits and reviews and administrative proceedings include routine and special investigations by state insurance departments, state attorneys general, the U.S. Attorney General and subcommittees of the U.S. Congress. Such investigations, audits, reviews and administrative proceedings could result in the imposition of civil or criminal fines, penalties, other sanctions and additional rules, regulations or other restrictions on the Company's business operations. Any liability that may result from any one of these actions, or in the aggregate, could have a material adverse effect on the Company's financial position or results of operations.

The Company has no other known material contingencies.

Provisions for uncollectible amounts

At December 31, 2024 and 2023, the Company reported admitted assets of \$871,123 and \$288,081, respectively, in premiums receivable and amounts receivable relating to uninsured plans. Based upon the Company's experience, uncollectible receivables are not expected to exceed the nonadmitted balance of \$15,431 at December 31, 2024; therefore, no additional provision for uncollectible amounts has been recorded. The potential for any additional loss is not believed to be material to the Company's financial condition.

15. Leases

A. Lessee Operating Lease

The Company has no lessee leasing arrangements.

B. Lessor Leases

The Company has not entered into any operating leases as a lessor.

16. Information About Financial Instruments With Off-Balance Sheet Risk and Financial Instruments With Concentrations of Credit Risk

The Company has no significant financial instruments with off-balance sheet risk.

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of investment securities. All investment securities are managed by professional investment managers within policies authorized by the board of directors. Such policies limit the amounts that may be invested in any one issuer and prescribe certain investee company criteria. As of December 31, 2024, there were no significant concentrations.

17. Sale, Transfer and Servicing of Financial Assets and Extinguishments of Liabilities

A. Transfers of Receivables Reported as Sales

Not applicable at December 31, 2024 and 2023.

B. Transfer and Servicing of Financial Assets

Not applicable at December 31, 2024 and 2023.

C. Wash Sales

- (1) In the course of the Company's asset management, securities may be sold and reacquired within 30 days of the sale date to enhance the yield on the investments.
- (2) At December 31, 2024 and 2023, there were no wash sales involving securities with an NAIC designation of 3 or below or unrated.

18. Gain or Loss to the Reporting Entity from Uninsured Plans and the Uninsured Portion of Partially Insured Plans

A. Administrative Services Only ("ASO") Plans

Not applicable at December 31, 2024.

B. Administrative Services Contract ("ASC") Plans

Not applicable at December 31, 2024.

C. Medicare or Other Similarly Structured Cost-Based Reimbursement Contract

(1) The Company does not record revenue explicitly attributable to the cost share and reinsurance components of administered Medicare.

(2)	Receivable from	Related to	2024	2023
	Federal government	Medicare cost sharing and	\$ 535,271 \$	33,606
		reinsurance programs		

- (3) As no revenue is recorded in connection with the cost share and reinsurance components of the Company's Medicare or similarly structured cost-based reimbursement arrangements, the Company has recorded no allowances and reserves for the adjustment of recorded revenues and receivables.
- (4) The Company has made no adjustment to revenue resulting from the audit of cost-reimbursement receivables related to revenues recorded in the prior period.

19. Direct Premium Written/Produced by Managing General Agents/Third Party Administrators

No premiums were written by managing general agents or third party administrators during the years ended December 31, 2024 and 2023.

20. Fair Value Measurements

A.

- (1) There are no assets or liabilities measured at fair value as of December 31, 2024 and 2023.
- (2) There are no investments in Level 3 as of December 31, 2024 and 2023.
- (3) The Company's policy is to recognize transfers between Levels, if any, as of the beginning of the reporting period.
- (4) Fair values of bonds are based on quoted market prices, where available. These fair values are obtained primarily from third party pricing services, which generally use Level 1 or Level 2 inputs, for the determination of fair value to facilitate fair value measurements and disclosures. Level 2 securities primarily include United States government securities, corporate securities, securities from states, municipalities and political subdivisions, mortgage-backed securities and certain other asset-backed securities. For securities not actively traded, the pricing services may use quoted market prices of comparable instruments or discounted cash flow analyses, incorporating inputs that are currently observable in the markets for similar securities. Inputs that are often used in the valuation methodologies include, but are not limited to, broker quotes, benchmark yields, credit spreads, default rates and prepayment speeds. The Company has controls in place to review the pricing services' qualifications and procedures used to determine fair values. In addition, the Company periodically reviews the pricing services' pricing methodologies, data sources and pricing inputs to ensure the fair values obtained are reasonable.

Certain bonds, primarily corporate debt securities, are designated Level 3. For these securities, the valuation methodologies may incorporate broker quotes or discounted cash flow analyses using assumptions for inputs such as expected cash flows, benchmark yields, credit spreads, default rates and prepayment speeds that are not observable in the markets.

There have been no significant changes in the valuation techniques during the current period.

B. Fair Value Measurements Under Other Accounting Pronouncements

Not applicable at December 31, 2024 and 2023.

C. Financial Instruments

Type of Financial Instrument		Admitted Assets	(Level 1)	(Level 2)	(Level 3)	Net Asset Value (NAV)	Practicable (Carrying Value)
Bonds	\$ 110,453	\$ 116,581	s —	\$ 110,453	s —	s —	\$ —

D. Not Practicable to Estimate Fair Value

There are no financial instruments that were not practicable to estimate fair value.

E. Investments Measured at Net Asset Value

The Company has no investments measured at net asset value.

21. Other Items

A. Unusual or Infrequent Items

Not applicable at December 31, 2024 and 2023.

B. Troubled Debt Restructuring: Debtors

Not applicable at December 31, 2024 and 2023.

C. Other Disclosures

The Maine Bureau of Insurance requires that the Company maintain a risk-based capital at no less than the greater of 375% of authorized control level risk-based capital or the minimum surplus requirements of 24-A M.R.S Section 410.

D. Business Interruption Insurance Recoveries

The Company has reported no recoveries for business interruption for the years ended December 31, 2024 and 2023.

E. State Transferable and Non-Transferable Tax Credits

The Company did not have state transferable or non-transferable tax credits at December 31, 2024 and 2023.

F. Subprime Mortgage-Related Risk Exposure

- (1) The Company's investment strategy of providing safety and preservation of capital, sufficient liquidity to meet cash flow requirements and the attainment of a competitive after-tax investment return is supported by a well diversified portfolio consisting of many different types of investments. The portion of the Company's investment portfolio with subprime mortgage-related risk exposure is relatively small in comparison to the overall investment portfolio, and consists mainly of investment grade securities with no exposure to collateralized debt obligations. All mortgage related investments are monitored closely as part of the quarterly investment review performed by the Elevance Health Investment Impairment Review Committee.
- (2) The Company did not carry investments in subprime mortgage loans in its portfolio at December 31, 2024 or 2023.
- (3) The Company did not have subprime mortgage-related risk exposure at December 31, 2024 or 2023.
- (4) The Company did not underwrite Mortgage Guaranty or Financial Guaranty insurance coverage at December 31, 2024 or 2023.

G. Retained Assets

The Company does not have retained assets at December 31, 2024 and 2023.

H. Insurance-Linked Securities Contracts

Not applicable.

I. The Amount That Could Be Realized on Life Insurance Where the Reporting Entity is Owner and Beneficiary or Has Otherwise Obtained Rights to Control the Policy

Not applicable.

22. Events Subsequent

Subsequent events have been considered through February 27, 2025 for the statutory statement issued on February 28, 2025. There were no events occurring subsequent to December 31, 2024 requiring recognition or disclosure.

23. Reinsurance

A. Ceded Reinsurance Report

Section 1 - General Interrogatories

(1) Are any of the reinsurers that are listed in Schedule S as non-affiliated owned in excess of 10% or controlled, either directly or indirectly, by the Company or by any representative, officer, trustee, or director of the Company?

Yes () No (X)

If yes, give full details.

(2) Have any policies issued by the Company been reinsured with a company chartered in
a country other than the United States (excluding U.S. Branches of such companies)
that is owned in excess of 10% or controlled, directly or indirectly, by an insured, a
beneficiary, a creditor or an insured or any other person not primarily engaged in the
insurance business?

Yes () No (X)

If yes, give full details.

Section 2 - Ceded Reinsurance Report - Part A

(1) Does the Company have any reinsurance agreements in effect under which the reinsurer may unilaterally cancel any reinsurance for reasons other than for nonpayment of premium or other similar credits?

Yes () No (X)

If yes, give full details.

(2) Does the reporting entity have any reinsurance agreements in effect such that the amount of losses paid or accrued through the statement date may result in a payment to the reinsurer of amounts that, in aggregate and allowing for offset of mutual credits from other reinsurance agreements with the same reinsurer, exceed the total direct premium collected under the reinsured policies?

Yes () No (X)

If yes, give full details.

Section 3 - Ceded Reinsurance Report - Part B

(1) What is the estimated amount of the aggregate reduction in surplus, (for agreements other than those under which the reinsurer may unilaterally cancel for reasons other than for nonpayment of premium or other similar credits that are reflected in Section 2 above) of termination of ALL reinsurance agreements, by either party, as of the date of this statement? Where necessary, the Company may consider the current or anticipated experience of the business reinsured in making this estimate.

\$0

(2) Have any new agreements been executed or existing agreements amended, since January 1 of the year of this statement, to include policies or contracts that were in force or which had existing reserves established by the Company as of the effective date of the agreement?

Yes () No (X)

If yes, give full details.

B. Uncollectible Reinsurance

The Company has no uncollectible reinsurance at December 31, 2024 and 2023.

C. Commutation of Ceded Reinsurance

The Company has not commuted ceded reinsurance during 2024 and 2023.

D. Certified Reinsurer Rating Downgraded or Status Subject Revocation

	revocations during 2024 and 2023.
E.	Reinsurance Credit
	(1) Not applicable.
	(2) Not applicable.
	(3) Not applicable.
	(4) Not applicable.
	(5) Not applicable.
24. Re	trospectively Rated Contracts & Contracts Subject to Redetermination
A.	The Company sells accident and health policies for which the premiums vary based on loss experience. The Company estimates retrospective premium adjustments through the review of each retrospectively rated account, comparing the claim development with that anticipated in the policy contracts.
В.	The Company records accrued retrospective premium as an adjustment to earned premium.
C.	100% of the net premium written is subject to retrospective rating features.
D.	Not applicable.
E.	Risk-Sharing Provisions of the ACA
	(1) Did the reporting entity write accident and health insurance premium that is subject to the Affordable Care Act risk-sharing provisions (YES/NO)?No
	(2) Impact of Risk-Sharing Provisions of the Affordable Care Act on Admitted Assets, Liabilities and Revenue for the Current Year
	Not applicable.
	(3) Roll-forward of prior year ACA risk-sharing provisions for the following asset (gross of any nonadmission) and liability balances, along with the reasons for adjustments to

Not applicable.

prior year balance.

25. Change in Incurred Claims and Claim Adjustment Expenses

- **A.** The estimated cost of claims and claim adjustment expense attributable to insured events of prior years decreased by \$340,950 during 2024. This is approximately 25.9% of unpaid claims and claim adjustment expenses of \$1,313,927 as of December 31, 2023. The redundancy reflects the decreases in estimated claims and claims adjustment expenses as a result of claims payment during the year, and as additional information is received regarding claims incurred prior to 2024. Recent claim development trends are also taken into account in evaluating the overall adequacy of unpaid claims and unpaid claim adjustment expense.
- **B.** There were no significant changes in methodologies and assumptions used in calculating the liability for unpaid losses and loss adjustment expenses.

26. Intercompany Pooling Arrangements

Not applicable at December 31, 2024 and 2023.

27. Structured Settlements

Not applicable at December 31, 2024 and 2023.

28. Health Care Receivables

A. Pharmaceutical Rebate Receivables

Quarter	Estimated Pharmacy Rebates as Reported on Financial Statements	Pharmacy Rebates as Billed or Otherwise Confirmed	Actual Rebates Received Within 90 Days of Billing	Actual Rebates Received Within 91 to 180 Days of Billing	Actual Rebates Received More Than 180 Days After Billing
12/31/2024	\$ 85,220	\$ 298,146	\$ 212,927	\$ —	\$ —
9/30/2024	106,457	234,073	223,501	_	
6/30/2024	80,688	213,859	187,363	26,497	_
3/31/2024	89,661	194,926	178,123	16,803	_
12/31/2023	\$ 54,857	\$ 200,923	\$ 191,929	\$ 8,994	\$ —
9/30/2023	56,093	185,958	178,720	7,238	_
6/30/2023	57,031	143,951	137,156	6,795	_
3/31/2023	75,465	158,908	141,028	17,879	_
12/31/2022	\$ 40,623	\$ 170,651	\$ 152,801	\$ 17,851	\$ —
9/30/2022	43,784	142,631	130,485	12,146	_
6/30/2022	27,665	135,075	120,854	14,221	_
3/31/2022	28,389	92,365	87,894	4,472	_

Note: Amounts within column "Estimated pharmacy rebates as reported on financial statements" include \$0 of uninsured admitted pharmacy rebate receivables at December 31, 2024 that are reported within Pg 2, Ln 17 "Amounts receivable relating to uninsured plans."

B. Risk Sharing Receivables

Not applicable at December 31, 2024.

29. Participating Policies

Not applicable at December 31, 2024 and 2023.

30. Premium Deficiency Reserves

1.	Liability carried for premium deficiency reserves	\$		
2.	Date of the most recent evaluation of this liability		December 31,	2024
3.	Was anticipated investment income utilized in the calculation?	Yes	No	X

The Company recorded premium deficiency reserves of \$ 953,194 at December 31, 2023.

31. Anticipated Salvage and Subrogation

Not applicable.

GENERAL INTERROGATORIES

PART 1 - COMMON INTERROGATORIES GENERAL

1.1	Is the reporting entity a member of an Insurance Holding Company System consisting of two or more affiliated persons, one or more of which is an insurer? If yes, complete Schedule Y, Parts 1, 1A, 2 and 3.		Yes [X] No []
1.2	If yes, did the reporting entity register and file with its domiciliary State Insurance Commissioner, Director or Superintendent or with such regulatory official of the state of domicile of the principal insurer in the Holding Company System, a registration statement providing disclosure substantially similar to the standards adopted by the National Association of Insurance Commissioners (NAIC) in its Model Insurance Holding Company System Regulatory Act and model regulations pertaining thereto, or is the reporting entity subject to standards and disclosure requirements substantially similar to those required by such Act and regulations?	s [X]	No [] N/A [1
1.3	State Regulating?		Maiı	ne	
1.4	Is the reporting entity publicly traded or a member of a publicly traded group?		Yes [X] No []
1.5	If the response to 1.4 is yes, provide the CIK (Central Index Key) code issued by the SEC for the entity/group		000115	6039	
2.1	Has any change been made during the year of this statement in the charter, by-laws, articles of incorporation, or deed of settlement of the reporting entity?		Yes [] No [X]
2.2	If yes, date of change:				
3.1	State as of what date the latest financial examination of the reporting entity was made or is being made.		12/31/	2022	
3.2	State the as of date that the latest financial examination report became available from either the state of domicile or the reporting entity. This date should be the date of the examined balance sheet and not the date the report was completed or released				
3.3	State as of what date the latest financial examination report became available to other states or the public from either the state of domicile or the reporting entity. This is the release date or completion date of the examination report and not the date of the examination (balance sheet date).				
3.4	By what department or departments? State of Maine Bureau of Insurance				
3.5	Have all financial statement adjustments within the latest financial examination report been accounted for in a subsequent financial statement filed with Departments?	; []	No [] N/A [Х]
3.6	Have all of the recommendations within the latest financial examination report been complied with?	; []	No [] N/A [Х]
4.1	During the period covered by this statement, did any agent, broker, sales representative, non-affiliated sales/service organization or any combination thereof under common control (other than salaried employees of the reporting entity) receive credit or commissions for or control a substantial part (more than 20 percent of any major line of business measured on direct premiums) of: 4.11 sales of new business?] No [X	
4.2	4.12 renewals? During the period covered by this statement, did any sales/service organization owned in whole or in part by the reporting entity or an affiliate receive credit or commissions for or control a substantial part (more than 20 percent of any major line of business measured on direct		Yes [] No [X	1
	premiums) of: 4.21 sales of new business?] No [X] No [X	
5.1	Has the reporting entity been a party to a merger or consolidation during the period covered by this statement?		Yes [] No [X]
5.2	If yes, provide the name of the entity, NAIC company code, and state of domicile (use two letter state abbreviation) for any entity that has ceased to exist as a result of the merger or consolidation.				
	1 Name of Entity NAIC Company Code State of Domicile				
6.1	Has the reporting entity had any Certificates of Authority, licenses or registrations (including corporate registration, if applicable) suspended revoked by any governmental entity during the reporting period?		Yes [] No [X]
6.2	If yes, give full information				
7.1	Does any foreign (non-United States) person or entity directly or indirectly control 10% or more of the reporting entity?		Yes [] No [X]
7.2	If yes, 7.21 State the percentage of foreign control				%
	1 2 Nationality Type of Entity	7			

8.1 8.2	Is the company a subsidiary of a depository institution holding company of the response to 8.1 is yes, please identify the name of the DIHC.					Yes []	No [Х]
8.3 8.4	Is the company affiliated with one or more banks, thrifts or securities fir If response to 8.3 is yes, please provide below the names and location federal financial regulatory services agency [i.e. the Federal Reserve B Federal Deposit Insurance Corporation (FDIC) and the Securities Exchargulator.	s (city and state of the main office) of any affiliates Board (FRB), the Office of the Comptroller of the Co	regulate	ed by a	he	Yes []	No [Х]
	1	2	3	4	5				
	Affiliate Name	Location (City, State)	FRB	OCC	FDI	C SEC			
8.5 8.6 9.	Is the reporting entity a depository institution holding company with sign Federal Reserve System or a subsidiary of the depository institution holding the sponse to 8.5 is no, is the reporting entity a company or subsidiary Federal Reserve Board's capital rule? What is the name and address of the independent certified public according to the sponsor of the substitution holding company with sign substitution holding company or substitution holding company or substitution holding company with sign substitution holding company with substitution holding compa	of a company that has otherwise been made subje	ect to the	······································		Yes [] No [
0.	Ernst & Young LLP, 111 Monument Circle, Suite 4000, Indianapolis, IN	6							
10.1	Has the insurer been granted any exemptions to the prohibited non-aur requirements as allowed in Section 7H of the Annual Financial Reportil law or regulation?	ng Model Regulation (Model Audit Rule), or substa	intially s	milar sta	ate	Yes []	No [Хј
10.310.4	Has the insurer been granted any exemptions related to the other requallowed for in Section 18A of the Model Regulation, or substantially sin If the response to 10.3 is yes, provide information related to this exemption.	nilar state law or regulation?i				Yes []	No [Х]
10.5	Has the reporting entity established an Audit Committee in compliance					X 1 No f	1	N/A	· []
10.6	If the response to 10.5 is no or n/a, please explain.	•			-	x] 110 [,	14,71	. ,
11. 12.1		rting entity or actuary/consultant associated with a ication? 8 Napa St. Winnetka, CA 91306	n actuar	al consu	ulting	Yes []	No [Х]
		usted carrying value							
12.2	If yes, provide explanation	, , ,				·			
13.	FOR UNITED STATES BRANCHES OF ALIEN REPORTING ENTITI	ES ONLY:							
13.1	What changes have been made during the year in the United States m	anager or the United States trustees of the reporti	ng entity	?					
13.2	, ,					Yes []	No []
13.3	Have there been any changes made to any of the trust indentures during	9 ,				Yes [-	No [-
13.4 14.1	If answer to (13.3) is yes, has the domiciliary or entry state approved the Are the senior officers (principal executive officer, principal financial off similar functions) of the reporting entity subject to a code of ethics, which is the province of the code of ethics of eth	ficer, principal accounting officer or controller, or pe	ersons p	erformin	g] No [Yes [X	-		
	 a. Honest and ethical conduct, including the ethical handling of actual or relationships; b. Full, fair, accurate, timely and understandable disclosure in the period. Compliance with applicable governmental laws, rules and regulation d. The prompt internal reporting of violations to an appropriate person de. Accountability for adherence to the code. 	or apparent conflicts of interest between personal and odic reports required to be filed by the reporting ent s;	and profe			100 [X	,	NO [1
14.11	If the response to 14.1 is No, please explain:								
	Has the code of ethics for senior managers been amended?	nt(s).				Yes [X]	No []
14.3	the Gifts and Special Courtesies section to ensure language on the progovernment officials, 3. Changes to the Code of Conduct to strengthen grievance process, 4. Added provisions for the use of Generative Al and / suppliers are required to adhere to RAI policies and guidelines, 5. Add Have any provisions of the code of ethics been waived for any of the specific process.	ocess for requesting an exception to the prohibition and clarify the scope and guiding principles for hund d Large Language Models (LLMs) and expanded to ded references to the Ireland Criminal Justice Act.	on gifts man righ clarify	to its and th that vend	he dors	Yes []	No [Х]
14.31	If the response to 14.3 is yes, provide the nature of any waiver(s).								

SVO Bank Lis	g entity the beneficiary of a Letter of Credit that is unrelated to re st?et is unrelated to re e to 15.1 is yes, indicate the American Bankers Association (AB/			Yes [] !	No [X
	etter of Credit and describe the circumstances in which the Letter		g g			
1 American Bankers Association (ABA) Routin			3		4	
Number	Issuing or Confirming Bank Name		Can Trigger the Letter of Credit		nount	
	BOARD OF	FDIRECTORS				
	e or sale of all investments of the reporting entity passed upon e	either by the board of dire		Yes [X	.]	No [
Does the repo	orting entity keep a complete permanent record of the proceeding	gs of its board of director	s and all subordinate committees	Yes [X]	No [
part of any of	ting entity an established procedure for disclosure to its board of its officers, directors, trustees or responsible employees that is ir	n conflict or is likely to co	nflict with the official duties of such	Yes [X	. 1 '	No [
po100111				.00 [//		
Has this state	FINA ment been prepared using a basis of accounting other than Statu	ANCIAL	as (a.g. Canarally Assented			
Accounting Pr	rnent been prepared using a basis of accounting other than state inciples)?	Pi	es (e.g., Generally Accepted	Yes [] [No [)
	loaned during the year (inclusive of Separate Accounts, exclusive					
			12 To stockholders not officers	.\$		
		20.	13 Trustees, supreme or grand (Fraternal Only)	¢		
2 Total amount	of loans outstanding at the end of year (inclusive of Separate Ac	counts, exclusive of				
policy loans):		20.2	21 To directors or other officers			
			22 To stockholders not officers23 Trustees, supreme or grand (Fraternal Only)	·		
 Were any ass obligation beir 	ets reported in this statement subject to a contractual obligation ng reported in the statement?	to transfer to another par	ty without the liability for such			
2 If yes, state th	e amount thereof at December 31 of the current year:		21 Rented from others			
			22 Borrowed from others			
			23 Leased from others			
Does this stat	ement include payments for assessments as described in the Ar	21.2 21.2 Statement Instructi	24 Other	.\$		
quaranty asso	ciation assessments?	inual Statement instructi		Yes [] [No [
2 If answer is ye			Amount paid as losses or risk adjustment			
			Amount paid as expenses			
			Other amounts paid			
	orting entity report any amounts due from parent, subsidiaries or	_		-	-	-
Does the insu	e any amounts receivable from parent included in the Page 2 am rer utilize third parties to pay agent commissions in which the an	nounts advanced by the t	hird parties are not settled in full within	. \$ Yes [
	e to 24.1 is yes, identify the third-party that pays the agents and			169 [, ,	NO [A
		1-4				
	Name of Third Dark	Is the Third-Party Agent a Related Party				
	Name of Third-Party	(Yes/No)				
	INVE	STMENT				
	stocks, bonds and other securities owned December 31 of current sesssion of the reporting entity on said date? (other than securities			Yes [X	1	No [

25.02	If no, give full and complete information, relating thereto			
25.03	For securities lending programs, provide a description of the program incl whether collateral is carried on or off-balance sheet. (an alternative is to r	reference Note 17 where this information is also provided)		
25.04	For the reporting entity's securities lending program, report amount of coll Instructions.		\$	0
25.05	For the reporting entity's securities lending program, report amount of coll	lateral for other programs.	\$	0
25.06	Does your securities lending program require 102% (domestic securities) outset of the contract?] No [] N/A [Χ]
25.07	Does the reporting entity non-admit when the collateral received from the	counterparty falls below 100%? Yes [] No [] N/A [Χ]
25.08	Does the reporting entity or the reporting entity's securities lending agent conduct securities lending?] No [] N/A [Χ]
25.09	For the reporting entity's securities lending program state the amount of the	he following as of December 31 of the current year:		
	25.092 Total book/adjusted carrying value of reinvested of	oorted on Schedule DL, Parts 1 and 2 collateral assets reported on Schedule DL, Parts 1 and 2 ne liability page	\$	0
26.1	Were any of the stocks, bonds or other assets of the reporting entity owns control of the reporting entity or has the reporting entity sold or transferred force? (Exclude securities subject to Interrogatory 21.1 and 25.03)	any assets subject to a put option contract that is currently in	Yes [X] No []
26.2	If yes, state the amount thereof at December 31 of the current year:	26.21 Subject to repurchase agreements	\$\$\$\$\$\$\$	0
26.3	For category (26.26) provide the following:			7
	Nature of Restriction	2 Description	3 Amount	_
07.4	Does the seconding onlike house any hodeing transactions reported as Coh	adula DD2	V [] N- [V	_
27.1 27.2	Does the reporting entity have any hedging transactions reported on Sche If yes, has a comprehensive description of the hedging program been ma If no, attach a description with this statement.			•
INES 2	27.3 through 27.5: FOR LIFE/FRATERNAL REPORTING ENTITIES ONLY	<i>'</i> :		
27.3	Does the reporting entity utilize derivatives to hedge variable annuity guar	rantees subject to fluctuations as a result of interest rate sensitivity?	Yes [] No [X]
27.4	27.42 Permi	ial accounting provision of SSAP No. 108itted accounting practice accounting guidance	Yes [] No []
27.5	following: The reporting entity has obtained explicit approval from the domi Hedging strategy subject to the special accounting provisions is a Actuarial certification has been obtained which indicates that the reserves and provides the impact of the hedging strategy within t Financial Officer Certification has been obtained which indicates	iciliary state. consistent with the requirements of VM-21. hedging strategy is incorporated within the establishment of VM-21	Yes [] No [1
28.1	Were any preferred stocks or bonds owned as of December 31 of the cur issuer, convertible into equity?		Yes [] No [X]
28.2	If yes, state the amount thereof at December 31 of the current year		\$	0
29.	Excluding items in Schedule F. Part 3 - Special Deposits, real estate, mo	rtgage loans and investments held physically in the reporting entity's		
23.	offices, vaults or safety deposit boxes, were all stocks, bonds and other scustodial agreement with a qualified bank or trust company in accordance Outsourcing of Critical Functions, Custodial or Safekeeping Agreements	e with Section 1, III - General Examination Considerations, F.	Yes [X] No []
	offices, vaults or safety deposit boxes, were all stocks, bonds and other secustodial agreement with a qualified bank or trust company in accordance	e with Section 1, III - General Examination Considerations, F. of the NAIC Financial Condition Examiners Handbook?	Yes [X] No []
	offices, vaults or safety deposit boxes, were all stocks, bonds and other scustodial agreement with a qualified bank or trust company in accordance Outsourcing of Critical Functions, Custodial or Safekeeping Agreements	e with Section 1, III - General Examination Considerations, F. of the NAIC Financial Condition Examiners Handbook?]

GENERAL INTERROGATORIES

9.02	For all agreements that do not comply with the requirements of the NAIC Financial Condition Examiners Handbook, provide the name, location
	and a complete explanation:

Name(s)		2 Location(s	s)		3 Complete Explanation	n(s)	
]
Have there been any changes, including name of the first fir	•	stodian(s) identified	in 29.01 during the cur	rent year	r?	Yes [] No [Х]
1 Old Custodian	Nev	2 w Custodian	3 Date of Cha	ange	4 Reason		

29.05 Investment management – Identify all investment advisors, investment managers, broker/dealers, including individuals that have the authority to make investment decisions on behalf of the reporting entity. This includes both primary and sub-advisors. For assets that are managed internally by employees of the reporting entity, note as such. ["...that have access to the investment accounts"; "...handle securities"]

1	2
Name of Firm or Individual	Affiliation
Loomis, Sayles & Company, LP	U

29.0597 For those firms/individuals listed in the table for Question 29.05, do any firms/individuals unaffiliated with the reporting entity (i.e., Yes [X] No [] designated with a "U") manage more than 10% of the reporting entity's invested assets?. 29.0598 For firms/individuals unaffiliated with the reporting entity (i.e., designated with a "U") listed in the table for Question 29.05, does the total assets under management aggregate to more than 50% of the reporting entity's invested assets?..... Yes [X] No []

29.06 For those firms or individuals listed in the table for 29.05 with an affiliation code of "A" (affiliated) or "U" (unaffiliated), provide the information for the table below.

1	2	3	4	5
				Investment
				Management
Central Registration				Agreement
Depository Number	Name of Firm or Individual	Legal Entity Identifier (LEI)	Registered With	(IMA) Filed
			Securities Exchange	
105377	Loomis, Sayles & Company, LP	JIZPN2RX3UMN0YIDI313	Commission	NO

Does the reporting entity have any diversified mutual funds reported in Schedule D - Part 2 (diversified according to the Securities and Exchange Commission (SEC) in the Investment Company Act of 1940 [Section 5(b)(1)])? Yes [] No [X]

If yes, complete the following schedule:

29.03 29.04

1	2	3
		Book/Adjusted
CUSIP#	Name of Mutual Fund	Carrying Value
30.2999 - Total		0

30.3 For each mutual fund listed in the table above, complete the following schedule:

1	2	3	4
		Amount of Mutual	
		Fund's Book/Adjusted	
		Carrying Value	
	Name of Significant Holding of the	Attributable to the	Date of
Name of Mutual Fund (from above table)	Mutual Fund	Holding	Valuation

GENERAL INTERROGATORIES

31. Provide the following information for all short-term and long-term bonds and all preferred stocks. Do not substitute amortized value or statement value for fair value.

	1	2	3
			Excess of Statement
			over Fair Value (-), or Fair Value over
	Statement (Admitted)		Fair Value over
	Value	Fair Value	Statement (+)
31.1 Bonds	116,581	110,453	(6, 128)
31.2 Preferred stocks	0		0
31.3 Totals	116,581	110,453	(6, 128)

31.4	Describe the sources or methods utilized in determining the fair values:					
	Fair values were obtained from third-party pricing sources. If a security was not priced by a third-party pricing source, internal analytical systems or broker quotes were utilized.					
32.1	Was the rate used to calculate fair value determined by a broker or custodian for any of the securities in Schedule D?	Y	es []	No [Х]
32.2	If the answer to 32.1 is yes, does the reporting entity have a copy of the broker's or custodian's pricing policy (hard copy or electronic copy) for all brokers or custodians used as a pricing source?	Υ	es []	No []
32.3	If the answer to 32.2 is no, describe the reporting entity's process for determining a reliable pricing source for purposes of disclosure of fair value for Schedule D:					
33.1 33.2	Have all the filing requirements of the Purposes and Procedures Manual of the NAIC Investment Analysis Office been followed?	Y	es [Х]	No []
34.	By self-designating 5GI securities, the reporting entity is certifying the following elements of each self-designated 5GI security: a. Documentation necessary to permit a full credit analysis of the security does not exist or an NAIC CRP credit rating for an FE or PL security is not available. b. Issuer or obligor is current on all contracted interest and principal payments. c. The insurer has an actual expectation of ultimate payment of all contracted interest and principal. Has the reporting entity self-designated 5GI securities?	Υ	es [1	No [X]
35.	By self-designating PLGI securities, the reporting entity is certifying its compliance with the requirements as specified in the Purposes and Procedures Manual of the NAIC Investment Analysis Office (P&P Manual) for private letter rating (PLR) securities and the following elements of each self-designated PLGI security: a. The security was either: i. issued prior to January 1, 2018 (which is exempt from PLR filling requirements pursuant to the P&P Manual), or ii. issued from January 1, 2018 to December 31, 2021 and subject to a confidentiality agreement executed prior to January 1, 2022 which confidentiality agreement remains in force, for which an insurance company cannot provide a copy of a private letter rating rationale report to the SVO due to confidentiality or other contractual reasons ("waived submission PLR securities"). b. The reporting entity is holding capital commensurate with the NAIC Designation and NAIC Designation Category reported for the security. c. The NAIC Designation and NAIC Designation Category were derived from the credit rating assigned by an NAIC CRP in its legal capacity as a NRSRO which is shown on a current private letter rating, dated during the financial statement year, held by the insurer and available for examination by state insurance regulators. d. Other than for waived submission PLR securities, defined above, on or after January 1, 2024 for any PLR securities issued on or after January 1, 2022, if the reporting entity is not permitted to share this private credit rating or the private rating letter rationale report of the PL security with the SVO, it certifies that it is reporting it as an NAIC 5.B GI and may not assign any other self-designation. Has the reporting entity self-designated PLGI to securities, all of which meet the above requirement and as specified in the P&P Manual?	Υ	es [1	No [X]
36.	By assigning FE to a Schedule BA non-registered private fund, the reporting entity is certifying the following elements of each self-designated FE fund: a. The shares were purchased prior to January 1, 2019. b. The reporting entity is holding capital commensurate with the NAIC Designation reported for the security. c. The security had a public credit rating(s) with annual surveillance assigned by an NAIC CRP in its legal capacity as an NRSRO prior to January 1, 2019. d. The fund only or predominantly holds bonds in its portfolio. e. The current reported NAIC Designation was derived from the public credit rating(s) with annual surveillance assigned by an NAIC CRP in its legal capacity as an NRSRO. f. The public credit rating(s) with annual surveillance assigned by an NAIC CRP has not lapsed. Has the reporting entity assigned FE to Schedule BA non-registered private funds that complied with the above criteria?	Υ	es [1	No [X]
37.	By rolling/renewing short-term or cash equivalent investments with continued reporting on Schedule DA, Part 1 or Schedule E Part 2 (identified through a code (%) in those investment schedules), the reporting entity is certifying to the following: a. The investment is a liquid asset that can be terminated by the reporting entity on the current maturity date. b. If the investment is with a nonrelated party or nonaffiliate, then it reflects an arms-length transaction with renewal completed at the discretion of all involved parties. c. If the investment is with a related party or affiliate, then the reporting entity has completed robust re-underwriting of the transaction for which documentation is available for regulator review. d. Short-term and cash equivalent investments that have been renewed/rolled from the prior period that do not meet the criteria in 37.a - 37.c are reported as long-term investments. Has the reporting entity rolled/renewed short-term or cash equivalent investments in accordance with these criteria?]	No	[X]	N/A	[]

38.1	Does the reporting entity directly hold cryptocurrencies?			Yes [] No [X]
38.2	If the response to 38.1 is yes, on what schedule are they reported?				
39.1	Does the reporting entity directly or indirectly accept cryptocurrencies as payments for premium	s on policies?		Yes [] No [X]
39.2	If the response to 39.1 is yes, are the cryptocurrencies held directly or are they immediately cor 39.21 Held directly] No []
20.2	39.22 Immediately converted to U			Yes [] No []
39.3	If the response to 38.1 or 39.1 is yes, list all cryptocurrencies accepted for payments of premiur				
		2 Immediately converted to USD, rectly Held, or Both	3 Accepted for Payment of Premiums		
	OTHER				
40.1	Amount of payments to trade associations, service organizations and statistical or rating bureau	us, if any?		\$	0
40.2	List the name of the organization and the amount paid if any such payment represented 25% of service organizations, and statistical or rating bureaus during the period covered by this statement.		nts to trade associatio	ns,	
	1 Name		2 int Paid		
41.1	Amount of payments for legal expenses, if any?			\$	17,540
41.2	List the name of the firm and the amount paid if any such payment represented 25% or more of during the period covered by this statement.	f the total payments for le	gal expenses		
	1 Name	Amou	2 int Paid		
	Omelveny & Myers Nelson Mullins Rileys		5,540		
42.1	Amount of payments for expenditures in connection with matters before legislative bodies, office	ers, or departments of go	vernment, if any?	\$	272
42.2	List the name of the firm and the amount paid if any such payment represented 25% or more of connection with matters before legislative bodies, officers, or departments of government during				
	1 Name	Amou	2 int Paid		
	Preti Flaherty Beliveau Pachios LLP Serlin Haley		132		
	Lobbying expenses disclosed reflect amounts reported in the Lobbyist Disclosure Reports the Secretary of State as well as the cost of external contractors who provided lobbying the Company. The amount may include expenses that may have been paid by an affiliate on Company and, as a result, may not be included in the Underwriting Gain reported on page Annual Statement.	filed with services to behalf of the 4 of the 2024			

GENERAL INTERROGATORIES

PART 2 - HEALTH INTERROGATORIES

1.1 1.2 1.3	Does the reporting entity have any direct Medicare Supplement Insurance in fo If yes, indicate premium earned on U.S. business only		\$		
	1.31 Reason for excluding				
1.4	Indicate amount of earned premium attributable to Canadian and/or Other Alien				
1.5 1.6	Indicate total incurred claims on all Medicare Supplement Insurance.	Most current three years:	. \$		
1.0	Individual policies:	1.61 Total premium earned	¢		0
		1.62 Total incurred claims			
		1.63 Number of covered lives			
		All years prior to most current three years:			
		1.64 Total premium earned			0
		1.65 Total incurred claims			
		1.66 Number of covered lives			
17	Crown policies	Most surrent three years			
1.7	Group policies:	Most current three years:	•		0
		1.71 Total premium earned 1.72 Total incurred claims			
		1.72 Total incurred claims			
					0
		All years prior to most current three years: 1.74 Total premium earned			0
		1.75 Total incurred claims			
		1.76 Number of covered lives			
		1.76 Number of covered lives			0
2.	Health Test:				
		1 2 Current Year Prior Year			
	2.1 Premium Numerator				
	2.3 Premium Ratio (2.1/2.2)				
	2.4 Reserve Numerator				
	2.5 Reserve Denominator				
	2.6 Reserve Ratio (2.4/2.5)	1.000			
3.1	Has the reporting entity received any endowment or gift from contracting hospit returned when, as and if the earnings of the reporting entity permits?	tals, physicians, dentists, or others that is agreed will be	Yes [] No	[X]
3.2	If yes, give particulars:				
4.1	Have copies of all agreements stating the period and nature of hospitals', phys dependents been filed with the appropriate regulatory agency?		Yes [X] No	[]
4.2	If not previously filed, furnish herewith a copy(ies) of such agreement(s). Do the	ese agreements include additional benefits offered?	Yes [] No	[]
5.1	Does the reporting entity have stop-loss reinsurance?		Yes [] No	[X]
5.2	If no, explain:				
	Elevance Health, Inc. will assume, pay, and discharge the obligations in the ev	rent the Company is insolvent.			
5.3	Maximum retained risk (see instructions)	5.31 Comprehensive Medical	Q		
5.5	waximum retained risk (see instructions)	5.32 Medical Only			
		5.33 Medicare Supplement			
		5.34 Dental & Vision			
		5.35 Other Limited Benefit Plan	Φ		
		5.36 Other			
6.	Describe arrangement which the reporting entity may have to protect subscribe hold harmless provisions, conversion privileges with other carriers, agreements agreements:	ers and their dependents against the risk of insolvency including	•		
7.1	Does the reporting entity set up its claim liability for provider services on a serv	rice date basis?	Yes [X] No	[]
7.2	If no, give details				
8.	Provide the following information regarding participating providers:	8.1 Number of providers at start of reporting year 8.2 Number of providers at end of reporting year .			
9.1	Does the reporting entity have business subject to premium rate guarantees? .		Yes [] No	[X]
9.2	If yes, direct premium earned:	9.21 Business with rate guarantees between 15-36 months	\$		
		9.22 Business with rate guarantees over 36 months	\$		

10.1	Does the reporting entity have Incentive Pool, Withh	old or Bonus Ar	rangements in its p	provider contracts?	·		Yes [X]] No []	
10.2	10.2 If yes: 10.21 Maximum amount payable bonuses 10.22 Amount actually paid for year bonuses 10.23 Maximum amount payable withholds 10.24 Amount actually paid for year withhold							190,97	'5
11.1	Is the reporting entity organized as:			11.13 An Indivi	al Group/Staff Mod dual Practice Asso Model (combinatio	ciation (IPA), or,	Yes [] No [X]] No [X]] No [X]	
11.2 11.3 11.4	Is the reporting entity subject to Statutory Minimum (If yes, show the name of the state requiring such min If yes, show the amount required.	nimum capital a	nd surplus				\$] No [] <u>Main</u> 1,934,47	
11.5 11.6	Is this amount included as part of a contingency reself the amount is calculated, show the calculation 250 % of Health Risk-Basked Capital Authorized Co] No [X]	
12.	List service areas in which reporting entity is license	d to operate:							
			Name of Service						
13.1	Do you act as a custodian for health savings accoun	nts?					Yes [] No [X]	
13.2	If yes, please provide the amount of custodial funds	held as of the re	eporting date				\$		
13.3	Do you act as an administrator for health savings ac	counts?					Yes [] No [X]	
13.4	If yes, please provide the balance of funds administe	ered as of the re	porting date				\$		
14.1 14.2	Are any of the captive affiliates reported on Schedule If the answer to 14.1 is yes, please provide the follow		norized reinsurers?			Yes [] No [] N/A [X]
	1	2	3	4		Supporting Reserv			
	Company Name	NAIC Company Code	Domiciliary Jurisdiction	Reserve Credit	5 Letters of Credit	6 Trust Agreements	7 Other		
15.	Provide the following for individual ordinary life insur ceded):	rance* policies (I	U.S. business only	15.1 [15.2]	ar (prior to reinsura Direct Premium Wr Fotal Incurred Clain	ance assumed or itten	\$		
					number of Covered				•
	Term(whether full und		nary Life Insurance d underwriting, iet		app")				
	Whole Life (whether f	full underwriting,	, limited underwritir						
	Variable Life (with or Universal Life (with or		, ,						
	Variable Universal Life			antee)					
16.	Is the reporting entity licensed or chartered, registered	ed, qualified, eliç	gible or writing bus	iness in at least tw	o states?		Yes [] N	10 [X]	
16.1	If no, does the reporting entity assume reinsurance to domicile of the reporting entity?						Yes [] N	No [X]	

FIVE-YEAR HISTORICAL DATA

		1 2024	2 2023	3 2022	4 2021	5 2020
	Balance Sheet (Pages 2 and 3)					
1.	Total admitted assets (Page 2, Line 28)	7,257,786	6,475,996	7,135,571	4,889,788	2,439,996
2.	Total liabilities (Page 3, Line 24)					
3.	Statutory minimum capital and surplus requirement	1,934,475	1,936,898	1,935,768	2,189,578	28,763
4.	Total capital and surplus (Page 3, Line 33)					
	Income Statement (Page 4)					
5.	Total revenues (Line 8)	8,265,208	8,320,157	7,170,362	2,125,297	0
6.	Total medical and hospital expenses (Line 18)	6,862,880	7,760,867	7,956,585	1,839,263	0
7.	Claims adjustment expenses (Line 20)	257,746	421,259	378,688	214,943	0
8.	Total administrative expenses (Line 21)					
9.	Net underwriting gain (loss) (Line 24)					
10.	Net investment gain (loss) (Line 27)					
11.	Total other income (Lines 28 plus 29)					
12.	Net income or (loss) (Line 32)					
	Cash Flow (Page 6)					
13.	Net cash from operations (Line 11)	(426,678)	(641,183)	(1,510,985)	(226,259)	(2,412)
	Risk-Based Capital Analysis					
14.	Total adjusted capital	5,392,398	3,890,575	3,749,378	3,936,356	2,238,256
15.	Authorized control level risk-based capital					
	Enrollment (Exhibit 1)	·	·	·	·	
16.	Total members at end of period (Column 5, Line 7)	749	905	886	302	
17.	Total members months (Column 6, Line 7)					
	Operating Percentage (Page 4) (Item divided by Page 4, sum of Lines 2, 3 and 5) x 100.0					
18.	Premiums earned plus risk revenue (Line 2 plus Lines 3 and 5)	100.0	100.0	100.0	100.0	100.0
19.	Total hospital and medical plus other non-health (Lines 18 plus Line 19)					
20.	Cost containment expenses					
21.	Other claims adjustment expenses					
22.	Total underwriting deductions (Line 23)					
23.	Total underwriting gain (loss) (Line 24)	16.8	1.0	(50.7)	(40.1)	0.0
	Unpaid Claims Analysis (U&I Exhibit, Part 2B)					
24.	Total claims incurred for prior years (Line 17, Col. 5)	931,735	499 , 185	300 , 149	0	
25.	Estimated liability of unpaid claims-[prior year (Line 17, Col. 6)]	1,282,480	824,233	225,147	0	
	Investments In Parent, Subsidiaries and Affiliates					
26.	Affiliated bonds (Sch. D Summary, Line 12, Col. 1)					
27.	Affiliated preferred stocks (Sch. D Summary, Line 18, Col. 1)					
28.	Affiliated common stocks (Sch. D Summary, Line 24, Col. 1)				0	0
29.	Affiliated short-term investments (subtotal included in Schedule DA Verification, Col. 5, Line 10)					
30.	Affiliated mortgage loans on real estate					
31.	All other affiliated					
32.	Total of above Lines 26 to 31	0	0	0	0	0
33.	Total investment in parent included in Lines 26 to 31 above.					

NOTE: If a party to a merger, have the two most recent years of this exhibit been restated due to a merger in compliance with the disclosure				
requirements of SSAP No. 3, Accounting Changes and Correction of Errors?	Yes [] N	No []
If no, please explain:				

SCHEDULE T PREMIUMS AND OTHER CONSIDERATIONS Allocated by States and Territories 10 Federal Employees Health Annuity Premiums & Active Accident and Benefits Property/ Total Program Premiums Casualty Premiums Columns 2 Through 8 Deposit-Type Contracts Status Health Medicaid CHIP Title Other States, etc. (a) Premiums Title XVIII 1 Alabama .N. n 2. Alaska. ΑK .N. . 0 3. ΑZ Arizona. N. . 0 4. Arkansas AR .0 .N. California CA 5. .0 Colorado СО 7. Connecticut СТ .0 8. Delaware DE N. 0 9. District of Columbia DC N 0 Florida . 10. FL .N. .0 Georgia .. .0 11. GΑ .N. 12. Hawaii .. Н .0 13. Idaho 14. Illinois 0 15. Indiana INI ٥ 16. lowa IΑ .0 17. Kansas KS .N. . 0 Kentucky. 18. ΚY .N. .0 19. Louisiana LA 20. Maine .. .8,170,377 21. Maryland . MD . 0 22 Massachusetts ... MA .N. n 23 Michigan . MI N n 24. Minnesota MN .N. .0 Mississippi 25. MS .N. .0 26. Missouri .. МО 27. Montana 28. Nebraska NE . 0 29. Nevada .. NV N 0 30. New Hampshire NH N 0 31. New Jersey NJ .N. .0 32. New Mexico .. NM .0 .N. 33. New York NY .0 34. North Carolina0 35. North Dakota ND .0 36 Ohio ОН N n 37. Oklahoma ΟK .N. .0 38. Oregon OR N. . 0 39. Pennsylvania PA .0 .N. Rhode Island 40. RI .0 41. South Carolina 42. South Dakota .. SD .0 43. Tennessee ΤN N. . 0 44. Texas ΤX N 0 45. Utah .. UT .N. .0 46. Vermont VT .0 .N. 47. Virginia VA .0 48. Washington 49. West Virginia WV 0 50. Wisconsin ١//١ N ٥ 51. Wyoming WY N. .0 52. American Samoa AS N. .0 53. Guam GU .N. .0 Puerto Rico 54. PR .0 55. U.S. Virgin Islands .. VI 56. Northern Mariana Islands MP 57. Canada .N.. .0 58. Aggregate Other XXX. .0 .0 .0 Aliens 59. Subtotal .0 .8,170,377 .0 .0 .0 .0 .8,170,377 .0 Reporting Entity
Contributions for Employe 60 XXX. Benefit Plans Totals (Direct Business) 0 8,170,377 0 0 0 8,170,377 0 61 XXX DETAILS OF WRITE-INS 58001 XXX 58002. .XXX. 58003 XXX. Summary of remaining write-ins for Line 58 from 58998

above)	XXX	U	U	U	U	U	U	U	U	<u> </u>
(a) Active Status Counts:										-
 L - Licensed or Chartere 	d - Licensed insura	ance carrier or	domiciled RRG	}	1 4. Q - C	Qualified - Qual	ified or accredi	ted reinsurer		0
2. R - Registered - Non-do	miciled RRGs				0 5. N - N	lone of the abo	ve - Not allowe	ed to write busi	ness in the state	e 56

.0

.0

.0

.0

0

.0

XXX.

.0

.0

58999

overflow page Totals (Lines 58001 through 58003 plus 58998)(Line 58


^{3.} E - Eligible - Reporting entities eligible or approved to write surplus lines in the state. 0 (b) Explanation of basis of allocation by states, premiums by state, etc. N/A


BCBSA Licensee


Regulated Insurance Compan


Regulated BCBSA Licensee


ALL SUBSIDIARIES 100% OWNED AND LLC'S ARE CONTROLLED BY MEMBERS UNLESS OTHERWISE NOTED














40.6


SCHEDULE Y – INFORMATION CONCERNING ACTIVITIES OF INSURER MEMBERS OF A HOLDING COMPANY GROUP PART 1 – ORGANIZATIONAL CHART

BCBSA Licensee

Regulated Insurance Company


Regulated BCBSA Licensee

ALL SUBSIDIARIES 100% OWNED AND LLC'S ARE CONTROLLED BY MEMBERS UNLESS OTHERWISE NOTED



BCBSA Licensee
Regulated Insurance Company

Regulated BCBSA Licensee ALL SUBSIDIARIES 100% OWNED AND LLC'S ARE CONTROLLED BY MEMBERS UNLESS OTHERWISE NOTED Carelon, Inc. See Page 40 for Parent Info 82-3027094 G0490 Carelon Behavioral Health Holdings, Inc. CarelonRx, Inc. Carelon Insights, Inc. Nash Holding Carelon Health, Inc. Wellpoint IPA Holding Company, LLC Company, Inc. See Page 40.9 for Subsidiary Info (DE) 82-3062245 G0491 82-3300542 G0494 G0493 54-1230110 G0563 83-0892028 G0230 99-3881969 CarelonRx Pharmacy, Inc. Carelon Palliative Care, Inc. (DE) Carelon Management Services, LLC G0231 47-3025203 G0520 90-1057454 Wellpoint IPA of NY, LLC See Page 40.6 for Subsidiary Info 45-4985009 G0540 20-2076421 G0532 Carelon Medical Benefits Healthcare Subrogation Management, Inc. Group, L.L.C. 4600 Group Holdings, LLC (DE) (IL) (CA) 20-8188236 G0595 36-3692630 G0441 4600 Group, LLC (CA) Carelon Insights IPA of Carelon Health of Texas New York, LLC (NY) 81-4603181 G0594 G0596 85-0541810 Boehm & Associates, LLC (CA)




⁵ Wellpoint Corporation holds a 2% interest in Highland Investor Holdings, LLC, and ATH Holding Company, LLC holds the remaining 98% interest.


BCBSA Licensee Regulated Insurance Company Regulated BCBSA Licensee ALL SUBSIDIARIES 100% OWNED AND LLC'S ARE CONTROLLED BY MEMBERS UNLESS OTHERWISE NOTED Carelon Behavioral Health Holdings, Inc. See Page 40.7 for Parent Info G0563 54-1230110 Carelon Behavioral Carelon Behavioral Care, Inc. Health, Inc. (VA) 82-5334761 G0564 G0571 54-1414194 NAIC 15448 Carelon Behavioral Health Carelon Behavioral Health of NAIC 47025 Living Complete Carelon Behavioral Health IPA, Carelon Health Federal **OPTIONS Health** Carelon Health of California, Inc. Carelon Health of Technologies, Inc. Services, Inc. Strategies, LLC Care, Inc. New Jersey, Inc. (CA) Pennsylvania, Inc. (MD) (NY) (VA) (MA) 50% (DE) 04-3324848 G0567 95-4297571 G0572 23-2918735 G0576 02-0581429 G0125 13-3934920 G0577 45-4238555 G0579 46-2053405 G0578 54-1826967 G0581 50% Carelon Behavioral Health Strategies IPA, LLC (NY) Massachusetts Behavioral Health Partnership 45-5208205 G0568 (General Partnership) 04-3307857 G0584

BCBSA Licensee

Regulated Insurance Company Regulated BCBSA Licensee ALL SUBSIDIARIES 100% OWNED AND LLC'S ARE CONTROLLED BY MEMBERS UNLESS OTHERWISE NOTED Anthem Partnership Holding Company, LLC 81-3974489 90% 49% 75% 50% NAIC 16345 NAIC 14276 NAIC 17519 NAIC 14064 AIC 16298 NAIC 16168 NAIC 16145 Wellpoint South Community Care Health Plan of munity Care Health Plan o Wellpoint Delaware, Inc. APC PASSE, LLC Amerigroup Mississippi, Inc. CCHAILC® Carolina Inc. Louisiana, Inc.7 (DE) Kansas, Inc. 14 (SC) (DC) 81-4626605 G0660 82-1853423 26-4674149 82-1800037 G0670 45-3358287 G0631 81-4131800 G0655 82-3062789 95% 92-3489706 50% 50% NAIC 15951 GR Health Solutions, LLC 11 NAIC 16553 Momentum Health Community Care Health Plan of (PA) AMH Health, LLC 9 Partners, LLC 10 Nebraska, Inc. 12 (NC) 84-4672692 G8477 47-5456872 G0310 83-2435050 G0652 82-4684953 NAIC 16774 NAIC 12812 AMH Health Plans of Maine Inc (PA) 30-0326654 G8478 84-4181695 G0653 7 Community Care Health Plan of Louisiana. Inc. is a joint venture 75% owned by

- 7 Community Care Health Plan of Louisiana, Inc. is a joint venture 75% owned by Anthem Partnership Holding Company, LLC and 25% owned by Louisiana Health Service & Indemnity Company d/b/a Blue Cross and Blue Shield of Louisiana (non-affiliate)
- ⁸ CCHA, LLC is a joint venture 50% owned by Anthem Partnership Holding Company,
 LLC and 50% owned by Colorado Community Health Alliance, LLC (non-affiliate)
- ⁹ AMH Health, LLC is a joint venture 36% owned by MaineHealth (non-affiliate) and 64% owned by Anthem Partnership Holding Company, LLC
- Momentum Health Partners, LLC is a joint venture 50% owned by Anthem Partnership Holding Company, LLC and 50% owned by Blue Cross and Blue Shield of North Carolina (non-affiliate)
- ¹¹ GR Health Solutions, LLC is a joint venture 50% owned by Anthem Partnership Holding Company, LLC and 50% owned by Independence Blue Cross, LLC (nonaffiliate)
- 12 Community Care Health Plan of Nebraska, Inc. is a joint venture 95% owned by Anthem Partnership Holding Company, LLC and 5% owned by Blue Cross and Blue Shield of Nebraska, Inc. (non-affiliate).
- ¹³ APC PASSE, LLC (regulated entity) is a joint venture 49% owned by Anthem Partnership Holding Company, LLC and 51% owned by Arkansas Provider Coalition, LLC (non-affiliate).
- ¹⁴ Community Care Health Plan of Kansas, Inc. is a joint venture 90% owned by Anthem Partnership Holding Company, LLC, 5% owned by Blue Cross Blue Shield of Kansas, Inc. (non-affiliate) and 5% owned by Blue Cross and Blue Shield of Kansas City (non-affiliate).





OVERFLOW PAGE FOR WRITE-INS

NONE